




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07H 19/00, 21/04, C12N 15/64</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/38200</p> <p>(43) International Publication Date: 3 September 1998 (03.09.98)</p>
<p>(21) International Application Number: PCT/US98/03702</p> <p>(22) International Filing Date: 27 February 1998 (27.02.98)</p> <p>(30) Priority Data: 08/807,200 27 February 1997 (27.02.97) US</p> <p>(71) Applicant: MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 640 Memorial Drive, Cambridge, MA 02139 (US).</p> <p>(72) Inventors: HUNTER, John, J.; 15 Kimball Street, Cambridge, MA 02140 (US). SHYJAN, Andrew, W.; 25 Baker Road, Nahant, MA 01908 (US). WONG, Grace, H., W.; 100 Arlington Road, Brookline, MA 02167 (US).</p> <p>(74) Agent: FASSE, J., Peter; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).</p>		<p>(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: NUCLEIC ACIDS ENCODING CASPASE-8H AND CASPASE-8I



(57) Abstract

The present invention relates to the discovery and characterization of two novel forms of Caspase-8. The first Caspase-8 of the invention, Caspase-8h, encodes a 220 amino acid polypeptide which includes two FADD death effector domains. The second caspase of the invention, Caspase-8i, encodes an 81 amino acid polypeptide having one FADD death effector domain. The invention encompasses nucleic acid molecules encoding Caspase-8h and Caspase-8i, vectors containing these nucleic acid molecules, cells harboring recombinant DNA encoding Caspase-8h and/or Caspase-8i, host fusion proteins which include Caspase-8h and/or Caspase-8i, transgenic animals which express Caspase-8h and/or Caspase-8i, therapeutic methods, purified Caspase-8h, purified Caspase-8i, therapeutic compounds and methods employing Caspase-8h and Caspase-8i, and screening methods employing Caspase-8h and Caspase-8i.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	NK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NUCLEIC ACIDS ENCODING CASPASE-8H AND CASPASE-8I

The invention relates to the field of programmed cell death.

5

Background of the Invention

In multicellular organisms, homeostasis is maintained by balancing the rate of cell proliferation against the rate of cell death. Cell proliferation is influenced by numerous growth factors and the expression
10 of proto-oncogenes, which typically encourage progression through the cell cycle. In contrast, numerous events, including the expression of tumor suppressor genes, can lead to an arrest of cellular proliferation.

In differentiated cells, a particular form of cell
15 death called apoptosis is carried out when an internal suicide program is activated. This program can be initiated by a variety of external signals as well as signals that are generated within the cell in response to, for example, genetic damage. For many years, the
20 magnitude of apoptotic cell death was not appreciated because the dying cells are quickly eliminated by phagocytes, without an inflammatory response.

The mechanisms that mediate apoptosis have been intensively studied. These mechanisms involve the
25 activation of endogenous proteases, loss of mitochondrial function, and structural changes such as disruption of the cytoskeleton, cell shrinkage, membrane blebbing, and nuclear condensation due to degradation of DNA. The various signals that trigger apoptosis are thought to
30 bring about these events by converging on a common cell death pathway that is regulated by the expression of genes that are highly conserved from worms, such as

- 2 -

C. elegans, to humans. In fact, invertebrate model systems have been invaluable tools in identifying and characterizing the genes that control apoptosis. Through the study of invertebrates and more evolved animals, numerous genes that are associated with cell death have been identified, but the way in which their products interact to execute the apoptotic program is poorly understood.

Recently, several polypeptides were discovered which form a complex that transmits an apoptotic signal when the Fas/APO-1 receptor is bound (Boldin et al., *Cell* 85:803, 1996; Muzio et al., *Cell* 85:817, 1996). This receptor, also known as CD95, is present on the surface of a wide variety of cells (Boldin et al., *supra*; Muzio et al., *supra*). The Fas/APO-1 receptor and the TNF receptor (described below) are classified as members of the TNF/nerve growth factor receptor family and both share a region of homology designated the "death domain" (Boldin et al., *supra*; Muzio et al., *supra*). The death domain of the Fas/APO1 receptor interacts with FADD (Fas-associated protein with death domain, also known as MORT1) and RIP (receptor interacting protein), forming a complex that, when joined by Caspase-8, constitutes the Fas/APO-1 death-inducing signalling complex (Boldin et al., *supra*; Muzio et al., *supra*). The interaction between Fas/APO-1 and FADD is mediated by their respective C-terminal death domains (Chinnaiyan et al., *Cell* 81:505-512, 1995). Caspase-8 contains two N-terminal stretches of approximately 60 amino acids that are homologous to the DED of FADD (Muzio et al., *supra*). The remainder of Caspase-8 is highly homologous to the ICE/CED-3 family of cysteine proteases, which induce cell death if overexpressed. A number of forms of Caspase-8 have been described (Boldin et al., *supra*).

- 3 -

Caspase-8 may also be an important part of a second complex which is involved in cell death. This complex forms in association with the intracellular portion of the tumor necrosis factor (TNF) receptor (TNFR-1 or p55-R), and includes Caspase-8, TRADD (TNFR-1-associated death domain protein), and FADD/MORT1 (Boldin et al., *supra*; Muzio et al., *supra*).

Summary of the Invention

The present invention relates to the discovery and characterization of two novel forms of Caspase-8. The first Caspase-8 of the invention, Caspase-8h, encodes a 220 amino acid polypeptide which includes two FADD death effector domains. The second caspase of the invention, Caspase-8i, encodes an 81 amino acid polypeptide having one FADD death effector domain.

The invention encompasses nucleic acid molecules encoding Caspase-8h and Caspase-8i, vectors containing these nucleic acid molecules, cells harboring recombinant DNA encoding Caspase-8h and/or Caspase-8i, host fusion proteins which include Caspase-8h and/or Caspase-8i, transgenic animals which express Caspase-8h and/or Caspase-8i, recombinant knock-out animals which fail to express Caspase-8.

By "isolated nucleic acid molecule" is meant a nucleic acid molecule that is separated from either the 5' or the 3' coding sequence with which it is immediately contiguous in the naturally occurring genome of an organism. An isolated nucleic acid molecule is also referred to as "recombinant nucleic acid molecule."

The nucleic acid molecules of the invention can be inserted into transcription and/or translation vectors, as described below, which will facilitate expression of the insert. The nucleic acid molecules and the polypeptides they encode can be used directly as

- 4 -

diagnostic or therapeutic agents, or (in the case of a polypeptide) can be used to generate antibodies that, in turn, are therapeutically useful. Accordingly, expression vectors containing the nucleic acid of the invention, cells transfected with these vectors, the polypeptides expressed, and antibodies generated, against either the entire polypeptide or an antigenic fragment thereof, are among the preferred embodiments.

As used herein, the term "transfected cell" means any cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid encoding a polypeptide of the invention (e.g., a Caspase-8h polypeptide or a Caspase-8i polypeptide).

As used herein, both "protein" and "polypeptide" mean any chain of amino acid residues, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). The polypeptides of the invention are referred to as "substantially pure," meaning that they are at least 60% by weight (dry weight) the polypeptide of interest, e.g., a Caspase-8 polypeptide or a Caspase-8i polypeptide. Preferably, the polypeptide is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, the polypeptide of interest. Purity can be measured by any appropriate standard method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. The polypeptide can be a naturally occurring, synthetic, or a recombinant molecule consisting of a hybrid with one portion, for example, being encoded by all or part of the Caspase-8h or Caspase-8i gene, and a second portion being encoded by all or part of a second gene. For example, the AZB polypeptide may be fused to a hexa-histidine tag to facilitate purification of bacterially expressed

- 5 -

protein, or to a hemagglutinin tag to facilitate purification of protein expressed in eukaryotic cells.

The polypeptides of the invention can also be chemically synthesized, or they can be purified from
5 tissues in which they are naturally expressed, according to standard biochemical methods of purification.

Also included in the invention are "functional polypeptides," which possess one or more of the biological functions or activities of the caspase-8h or
10 caspase-8i. These functions or activities are described in detail below and concern, primarily, inhibition of apoptosis and/or the ability to bind some or all of the proteins which normally bind to caspase-8h or caspase-8i. A functional polypeptide is also considered within the
15 scope of the invention if it serves as an immunogen for production of antibodies that specifically bind to caspase-8h or caspase-8i. In many cases, functional polypeptides retain one or more domains present in the naturally-occurring form of the polypeptide. For
20 example, a functional polypeptide may possess one or more FADD death effector domains. It is well within the abilities of skilled artisans to determine whether a polypeptide, regardless of size, retains the function activity of a polypeptide of the invention.

25 The functional polypeptides may contain a primary amino acid sequence that has been modified from those disclosed herein. Preferably these modifications consist of conservative amino acid substitutions, as described herein.

30 The members of a pair of molecules (for example, an antibody-antigen pair) are said to "specifically bind" to each other if they bind to each other with greater affinity than to other molecules, even those that are structurally or functionally related to a member of the
35 specific binding pair.

- 6 -

The invention also encompasses compounds which modulate the expression or activity of Caspase-8h and/or Caspase-8i, including small molecules (i.e., molecules with a molecular weight below about 500), large molecules
5 (i.e., molecules with a molecular weight above about 500), and nucleic acid molecules that can be used to inhibit the expression of these genes (for example, antisense and ribozyme molecules) or to enhance their expression (for example, expression constructs that place
10 nucleic acid sequences encoding either caspase-8h or caspase-8i under the control of a strong promoter system), and transgenic animals that express a caspase-8h or caspase-8i transgene. Because caspase-8 gene encodes a number of alternatively spliced forms of caspase-8, the
15 level of caspase-8h or caspase-8i expression can be altered by altering the splicing pattern of the caspase-8 primary RNA transcript.

Caspase-8h and/or Caspase-8i function can be altered either by altering the expression of Caspase-8h
20 and/or Caspase-8i (i.e., altering the amount of Caspase-8h and/or Caspase-8i present in a given cell) or by altering the activity of Caspase-8h and/or Caspase-8i (i.e., altering a Caspase-8h and/or Caspase-8i function, e.g., binding to Fas/APO-1 receptor complex).

25 The invention encompasses methods of treatment including a method of treating a patient who is suffering from a disorder associated with an abnormal rate of apoptotic cell death, abnormal activity of the Fas/APO-1 receptor complex, or abnormal activity of the TNF
30 receptor complex by administering a compound that modulates the expression of Caspase-8h and/or Caspase-8i (at the DNA, mRNA or protein level, e.g., by altering mRNA splicing) or by altering the activity of Caspase-8h and/or Caspase-8i. Examples of such compounds include
35 small molecules, antisense nucleic acid molecules, and

- 7 -

ribozymes. Because Caspase-8h and Caspase-8i lack the ICE/CED-3 domain that is required for carrying out apoptosis, but have FADD death effector domains required for interaction with Fas/APO-1, they may compete with
5 other forms of Caspase-8 for binding to the Fas/APO-1 complex. Accordingly, increased expression of Caspase-8h and/or Caspase-8i may decrease Fas/APO-1 mediated apoptosis (or TNF receptor mediated apoptosis). A patient who is suffering from an abnormally high rate of
10 apoptotic cell death may be treated by the administration of a ligand (for example, a synthetic ligand) that mediates oligomerization between the Fas/APO-1 receptor complex or the TNF receptor complex and Caspase-8h or Caspase-8i, increases the expression of Caspase-8h or
15 Caspase-8i, or increases the activity of Caspase-8h or Caspase-8i. Accordingly, the invention features therapeutic compositions that contain the compounds or ligands described above.

A patient who is suffering from a disorder
20 associated with excessive apoptotic cell death, abnormal activity of the Fas/APO-1 receptor complex, or abnormal activity of the TNF receptor complex can be treated by the administration of an expression vector that contains a nucleic acid molecule encoding Caspase-8h or Caspase-8i
25 by administering the polypeptide directly to the patient's cells (either in vivo or ex vivo). These methods are described more fully below.

Certain disorders are associated with an increased number of surviving cells, which are produced and
30 continue to survive or proliferate when apoptosis is inhibited. These disorders include cancer (particularly follicular lymphomas, carcinomas associated with mutations in p53, and hormone-dependent tumors such as breast cancer, prostate cancer, and ovarian cancer),
35 autoimmune disorders (such as systemic lupus

- 8 -

erythematosis, immune-mediated glomerulonephritis), and viral infections (such as those caused by herpesviruses, poxviruses, and adenoviruses).

Failure to remove autoimmune cells that arise during development or that develop as a result of somatic mutation during an immune response can result in autoimmune disease. One of the molecules that plays a critical role in regulating cell death in lymphocytes is the cell surface receptor for Fas.

Populations of cells are often depleted in the event of viral infection, with perhaps the most dramatic example being the cell depletion caused by the human immunodeficiency virus (HIV). Surprisingly, most T cells that die during HIV infections do not appear to be infected with HIV. Although a number of explanations have been proposed, recent evidence suggests that stimulation of the CD4 receptor results in the enhanced susceptibility of uninfected T cells to undergo apoptosis.

A wide variety of neurological diseases are characterized by the gradual loss of specific sets of neurons. Such disorders include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) retinitis pigmentosa, spinal muscular atrophy, and various forms of cerebellar degeneration. The cell loss in these diseases does not induce an inflammatory response, and apoptosis appears to be the mechanism of cell death.

In addition, a number of hematologic diseases are associated with a decreased production of blood cells. These disorders include anemia associated with chronic disease, aplastic anemia, chronic neutropenia, and the myelodysplastic syndromes. Disorders of blood cell production, such as myelodysplastic syndrome and some forms of aplastic anemia, are associated with increased

- 9 -

apoptotic cell death within the bone marrow. These disorders could result from the activation of genes that promote apoptosis, acquired deficiencies in stromal cells or hematopoietic survival factors, or the direct effects of toxins and mediators of immune responses.

Two common disorders associated with cell death are myocardial infarctions and stroke. In both disorders, cells within the central area of ischemia, which is produced in the event of acute loss of blood flow, appear to die rapidly as a result of necrosis. However, outside the central ischemic zone, cells die over a more protracted time period and morphologically appear to die by apoptosis.

In addition, the present invention encompasses methods and compositions for the diagnostic evaluation, typing, and prognosis of disorders associated with apoptotic cell death. The disorder can be associated with either an increase or a decrease in the incidence of apoptotic cell death. For example, the nucleic acid molecules of the invention can be used as diagnostic hybridization probes to detect, for example, expression of Caspase-8h or Caspase-8i. Such methods may be used to classify cells by the level of Caspase-8h or Caspase-8i expression. For example higher Caspase-8h or Caspase-8i expression may be associated with a lower rate of apoptosis.

Alternatively, the nucleic acid molecules can be used as primers for diagnostic PCR analysis for the identification of gene mutations, allelic variations and splice regulation defects in the caspase-8 gene. The present invention further provides for diagnostic kits for the practice of such methods.

In particular, the invention described below encompasses Caspase-8h and Caspase-8i, polypeptides corresponding to functional domains of Caspase-8h or

- 10 -

Caspase-8i (e.g., the "DED" domain), mutated, truncated, or deleted polypeptides that retain the functional activity of Caspase-8h and Caspase-8i (for example, a polypeptide in which one or more amino acid residues have
5 been substituted or deleted from the death effector domain), and fusion proteins (as described below).

Polypeptides that exhibit at least 70%, preferably at least 80%, more preferably 90%, and most preferably 95% of the activity of the Caspase-8h and Caspase-8i
10 polypeptides described herein are considered within the scope of the invention.

The invention encompasses nucleic acids and polypeptides that have a sequence that is substantially identical to a Caspase-8h or Caspase-8i nucleic acid or
15 polypeptide. The term "substantially identical" is hereby defined as a polypeptide or nucleic acid having a sequence has at least 90%, preferably 95%, and more preferably 98% or 99% or more identity to the sequence of a reference amino acid or nucleic acid sequence. For
20 polypeptides, the length of the reference polypeptide sequence will generally be at least 16 amino acids, at least 20 amino acids, at least 25 amino acids, or preferably 35 amino acids. For nucleic acids, the length of the reference nucleic acid sequence will generally be
25 at least 50 nucleotides, at least 60 nucleotides, at least 75 nucleotides, and or at least 110 nucleotides.

Sequence identity can be measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of
30 Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705) with the default parameters specified therein.

In the case of polypeptide sequences which are less than 100% identical to a reference sequence, the
35 non-identical positions are preferably, but not

- 11 -

necessarily, conservative substitutions for the reference sequence. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid
5 and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine.

Where a particular polypeptide is said to have a specific percent identity to a reference polypeptide of a
10 defined length, the percent identity is relative to the reference polypeptide. Thus, a peptide that is 50% identical to a reference polypeptide that is 100 amino acids long can be a 50 amino acid polypeptide that is completely identical to a 50 amino acid long portion of
15 the reference polypeptide. It might also be a 100 amino acid long polypeptide which is 50% identical to the reference polypeptide over its entire length. Of course, many other polypeptides will meet the same criteria.

The reference nucleic acid or polypeptide can be a
20 naturally-occurring molecule, for example, a Caspase-8h encoding nucleic acid molecule, a Caspase-8i encoding nucleic acid molecule, a Caspase-8h polypeptide, or a Caspase-8i polypeptide.

By "transgenic animal" is meant any animal
25 containing cells that bear genetic information received, directly or indirectly, by deliberate genetic manipulation at the subcellular level, such as DNA received by microinjection or by infection with recombinant virus. Thus, animals of the invention are
30 those with one or more cells that contain a recombinant DNA molecule of the invention and, in this context, the term "animal" denotes all animals except *Homo sapiens*. Farm animals (pigs, goats, sheep, cows, horses, rabbits, and the like), rodents (such as rats, guinea pigs, and
35 mice), non-human primates (for example, baboons, monkeys,

- 12 -

and chimpanzees), and domestic animals (for example, dogs and cats) are especially preferred.

It is also preferred that the nucleic acid molecule becomes integrated with the animal's
5 chromosomes, but the use of DNA sequences that replicate extrachromosomally, such as might be engineered into yeast artificial chromosomes, is also contemplated.

The term "transgenic animal" also includes animals in which the genetic information has been taken up and
10 integrated into a germ line cell. These animals typically have the ability to transfer the genetic information to their offspring. If the offspring in fact possess some or all of the genetic information delivered to the parent animal, then they, too, are transgenic
15 animals.

In another embodiment, the invention features methods of identifying compounds that modulates apoptotic cell death by modulating the expression or activity of Caspase-8h and/or Caspase-8i by assessing the expression
20 or activity of Caspase-8h and/or Caspase-8i in the presence and absence of said compound. A difference in the level of expression or activity in the presence of the compound (compared with the level of expression or activity in the absence of the compound) indicates that
25 the compound is capable of modulating apoptotic cell death by modulating the expression of Caspase-8h and/or Caspase-8i. Expression can be assessed either at the level of gene expression (e.g., by measuring mRNA) or protein expression by techniques that are well known to
30 skilled artisans. The activity of Caspase-8h and/or Caspase-8i can be assessed functionally, i.e., by assaying the ability of the compound to inhibit apoptosis following activation of the Fas/APO-1 or TNF receptor complexes.

- 13 -

The invention features an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide that is at least 85% identical to SEQ ID NO:2; and an isolated nucleic acid molecule comprising a
5 nucleotide sequence encoding a polypeptide that is at least 85% identical to SEQ ID NO:4. In one embodiment, the molecule encodes a polypeptide capable of selectively binding to the death effector domain of FADD.

In other aspects the invention features: an
10 isolated nucleic molecule encoding the amino acid sequence of SEQ ID NO:2, an isolated nucleic acid molecule which includes the nucleotide sequence of SEQ ID NO:3, an isolated nucleic acid molecule of claim which encodes the amino acid sequence of SEQ ID NO:4, and
15 isolated molecule of which includes the nucleotide sequence of SEQ ID NO:2, an isolated nucleic acid molecule which includes the molecule of ATCC 97877, and an isolated nucleic acid molecule which includes the molecule of ATCC 97878.

20 In another aspect the invention features a vector which includes an above-described nucleic acid molecule. In various specific embodiments, the vector is an expression vector, includes a regulatory element, includes a regulatory element selected from the group
25 consisting of the cytomegalovirus hCMV immediate early gene, the early promoter of SV40 adenovirus, the late promoter of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage λ , the control
30 regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α -mating factors, includes a regulatory element that directs tissue-specific expression, includes a reporter gene,
35 includes a reporter gene is selected from the group

- 14 -

consisting of β -lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo^r, G418^r), dihydrofolate reductase (DHFR),

- 5 hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding β -galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT), is a plasmid, is a virus, and is a retrovirus.

- 10 In another aspect, the invention features a genetically engineered host cell, particularly a eukaryotic cell, which includes an expression vector described above.

- 15 In other aspects, the invention features a substantially pure polypeptide having the amino acid sequence encoded by an above-described nucleic acid molecule. The invention also features a polypeptide which includes a heterologous polypeptide other than a Caspase-8 polypeptide.

- 20 In other aspects the invention features an antibody that binds Caspase-8h and an antibody that binds Caspase-8i.

In yet another aspect the invention features a transgenic animal harboring a nucleic acid molecule described above.

- 25 The invention also features a method for determining whether a patient is suffering from a disorder associated with an abnormal rate of apoptotic cell death, the method includes obtaining a biological sample (e.g., a tumor sample) from the patient and
30 quantitating the level of caspase-8h expression in the biological sample. In related methods the method includes quantitating mRNA encoding Caspase-8h or quantitating Caspase-8h protein.

- The invention also features a method for
35 determining whether a patient is suffering from a

- 15 -

disorder associated with an abnormal rate of apoptotic cell death, the method includes obtaining a biological sample (e.g., a tumor sample) from the patient and quantitating the level of caspase-8i expression in the
5 biological sample. In related methods the method includes quantitating mRNA encoding Caspase-8i or quantitating Caspase-8i protein.

Related methods entail an RNase protection assay, Northern blot analysis, amplification by RT-PCR, or
10 Western blot analysis.

The invention also features a method of treating a patient who is suffering from a disorder associated with abnormal activity of the Fas/APO-1 receptor complex, the method includes administering to the patient a compound
15 that modulates the expression or activity of Caspase-8h. In related methods the compound includes a small molecule, an antisense nucleic acid molecule, or a ribozyme.

The invention also includes a method of treating a
20 patient who is suffering from a disorder associated with an abnormal activity of the TNF receptor complex, the method includes administering to the patient a compound that modulates the expression or activity of Caspase-8i. In related methods the compound includes a small
25 molecule, an antisense nucleic acid molecule, or a ribozyme.

The invention also features therapeutic compositions which include the compounds of the above-described treatment methods.

30 In another aspect the invention features a method for treating a patient who is suffering from a disorder associated with abnormal activity of the Fas/APO-1 receptor complex, the method includes administering a compound that mediates oligomerization between the
35 Fas/APO-1 receptor complex and Caspase-8h or Caspase-8i.

- 16 -

The methods of the invention include a method for treating a patient who is suffering from a disorder associated with abnormal activity of the TNF receptor complex, the method includes administering a compound
5 that mediates oligomerization between the TNF receptor complex and Caspase-8h or Caspase-8i.

In related methods the patient is suffering from acquired immune deficiency syndrome (AIDS), a neurodegenerative disorder, a myelodysplastic syndrome,
10 an ischemic injury, or a toxin-induced injury. In other related methods, the compound is synthetic.

The invention also features, a method of treating a patient who is suffering from a disorder associated with excessive apoptotic cell death, the method including
15 administering to the patient a caspase-8h or caspase-8i nucleic acid molecule, and a method of treating a patient who is suffering from a disorder associated with excessive apoptotic cell death, the method including administering to the patient a Caspase-8h polypeptide or
20 a Caspase-8i polypeptide.

In another aspect the invention features a method of identifying a compound that modulates expression of Caspase-8h, the method includes assessing the expression of Caspase-8h in the presence and absence of the
25 compound.

In yet another aspect the invention features a method of identifying a compound that modulates expression of Caspase-8i, the method includes assessing the expression of Caspase-8i in the presence and absence
30 of the compound.

The invention features a method for treating a patient who is suffering from an abnormally low rate of apoptotic cell death, the method including administering a compound that mediates oligomerization between the
35 Fas/APO-1 receptor complex and Caspase-8h or Caspase-8i;

- 17 -

and a method for treating a patient who is suffering from an abnormally low rate of apoptotic cell death, the method including administering a compound that mediates oligomerization between the TNF receptor complex and
5 Caspase-8h or Caspase-8i.

The invention also features a method of identifying a compound that modulates the activity of Caspase-8h, the method including assessing the activity of Caspase-8h in the presence and absence of the
10 compound; and a method of identifying a compound that modulates the activity of Caspase-8i, the method including assessing the activity of Caspase-8i in the presence and absence of the compound.

In other aspects the invention includes a method
15 for determining whether a selected compound modulates oligomerization between the Fas/APO-1 receptor complex and Caspase-8h or Caspase-8i, the method including measuring oligomerization of the Fas/APO-1 receptor complex and Caspase-8h or Caspase-8i in the presence and
20 absence of the selected compound; and a method for determining whether a selected compound modulates oligomerization between the TNF receptor complex and Caspase-8h or Caspase-8i, the method including measuring oligomerization of the TNF receptor complex and Caspase-
25 8h or Caspase-8i in the presence and absence of the selected compound.

The invention features an isolated nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of
30 SEQ ID NO:1, the isolated nucleic acid molecule encoding Caspase-8h; an isolated nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:3, the isolated nucleic acid molecule encoding Caspase-8i;
35 an isolated nucleic acid molecule includes a nucleotide

- 18 -

sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO:1, the isolated nucleic acid molecule encoding Caspase-8h; and an isolated nucleic acid molecule includes a nucleotide sequence
5 which is at least 90% identical to the nucleotide sequence of SEQ ID NO:3, the isolated nucleic acid molecule encoding Caspase-8i.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as
10 commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are
15 described herein. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials,
20 methods, and examples are illustrative only and are not intended to be limiting.

Other features and advantages of the invention will be apparent from the detailed description and from the claims. Although materials and methods similar or
25 equivalent to those described herein can be used in the practice or testing of the invention, the preferred materials and methods are described below.

Brief Description of the Drawings

Fig. 1 is a schematic diagram illustrating the
30 proteins that interact with the Fas/APO-1 (left hand side) and p55 (right hand side) receptors and thereby participate in the induction of cell death.

Fig. 2 is a representation of the nucleic acid sequence of caspase-8h (SEQ ID NO:1).

- 19 -

Fig. 3 is a representation of the amino acid sequence of Caspase-8h (SEQ ID NO:2).

Fig. 4 is a representation of the nucleic acid sequence of caspase-8i (SEQ ID NO:3).

5 Fig. 5 is a representation of the amino acid sequence of Caspase-8i (SEQ ID NO:4).

Fig. 6 is a representation of the nucleic acid sequence of caspase-8 (SEQ ID NO:11).

10 Fig. 7 is a representation of the amino acid sequence of Caspase-8 (SEQ ID NO:12).

Fig. 8 is a schematic representation of Caspase-8 pre-mRNA, Caspase-8h mRNA (showing the location of the TAG stop codon), and Caspase-8i mRNA (showing the location of the TAA stop codon).

15 Detailed Description

The present invention relates to the discovery, identification, and characterization of two nucleic acid molecules that encode novel Caspase-8 polypeptides, i.e., Caspase-8h and Caspase-8i. These caspase molecules are
20 involved in signal transduction triggered by the activation of the Fas/APO1 (CD95) or p55 (TNFR1) receptors by virtue of their ability to bind FADD/MORT1 within the receptor complex. They lack, however, the ICE/CED-3 cysteine protease domain present in some forms
25 of Caspase-8. Therefore caspase-8h and caspase-8i do not transmit the signal generated by receptor binding, as the full-length Caspase-8 protein would.

Identification and Characterization of Nucleic Acid Molecules Encoding Caspase-8h and Caspase-8i

30 Standard techniques were used to generate cDNA from human placental mRNA, and the polymerase chain reaction (PCR) was performed to selectively amplify a portion of that cDNA. The reaction included two oligonucleotide primers that were based on the sequence

- 20 -

of caspase-8: 5'-ATGGACTTCAGCAGAAATCTTTATG-3' (SEQ ID NO:5) and 5'-TCAATCAGAAGGGAAGACAAGTTTT-3' (SEQ ID NO:6). The amplified cDNA fragment was subcloned into the plasmid vector pCR2.1 (InVitrogen, San Diego, CA), and 5 four independent clones were prepared. When these clones were analyzed by digestion with EcoRI, three different restriction maps were seen. Sequence analysis confirmed that three of the four clones were distinct and that they represented different forms of the caspase-8 gene. One 10 of the clone represented the presumptively full-length caspase-8 cDNA, as described by Muzio et al. (*Cell* 85:817-827, 1996) and Boldin et al. (*Cell* 85:803-815, 1996). The other two clones contained cDNA encoding novel forms of Caspase-8 that lack the ICE/CED-3 cysteine 15 protease domain present in full-length Caspase-8. According to the convention recently proposed (*Cell* 87:171, 1996), these forms have been named Caspase-8h and Caspase-8i.

Caspase-8h is predicted to encode a polypeptide 20 that is 220 amino acids in length and that contains two tandem domains that are similar to the FADD death effector domain (DED; see below). Caspase-8i is predicted to encode a much shorter polypeptide, of 81 amino acid residues, that consists of only the first 25 FADD DED-like domain.

Caspase-8 is believed to mediate the apoptotic signal that is generated when the Fas/APO-1 (CD95) receptor is bound by its natural ligand or specific agonist antibody (Baglioni, In "Tumor Necrosis Factors: 30 The Molecules and Their Emerging Role in Medicine," B. Beutler, Ed., Raven Press, New York, NY, pp. 425-438, 1992; Itoh et al., *J. Biol. Chem.* 268:10932-10937, 1993). It is thought that Caspase-8 also mediates the apoptotic signal that is generated when the TNF receptor (TNFR-1 or 35 p55-R) is bound by its natural ligand or specific agonist

- 21 -

antibody. Both of these receptors are members of the tumor necrosis factor (TNF)/nerve growth factor receptor family, which also includes TNFR-2, low affinity NGFR, CD40, CD30, and others (Smith et al., *Science* 5 248:1019-1023, 1990).

While the members of this receptor family are characterized by the presence of cysteine-rich repeats in their extracellular domains, Fas/APO-1 and TNFR-1 also share a region of homology that is designated the "death 10 domain" because it is required to signal apoptosis (Itoh and Nagata, *J. Biol. Chem.* 268:10932-10937, 1993). This shared death domain suggests that both receptors interact with a related set of signal-transducing molecules.

Three of these signal-transducing molecules were 15 recently discovered: TRADD (TNFR-1-associated death domain), FADD/MORT1 (Fas-associating protein with death domain), and RIP (receptor-interacting protein) (Chinnaiyan et al. *Cell* 81:505-512, 1995; Stanger et al., *Cell* 81:513-523, 1995; Hsu et al., *Cell* 81:495-504, 1995; 20 Cleveland and Ihle, *Cell* 81:479-482, 1995). The way in which these proteins are believed to interact with the Fas/APO1 and TNF receptors is illustrated in Fig. 1. A dominant negative version of FADD (FADD-DN) blocks both TNF-induced and CD95-induced apoptosis, suggesting that 25 FADD functions as the common signaling conduit for cytokine-mediated cell death (Chinnaiyan et al. *J. Biol. Chem.* 271:4961-4965, 1996; Hsu et al. *Cell* 84:299-308, 1996).

In addition, a protein that binds FADD/MORT1 has 30 been discovered. This protein was named FLICE by one group of investigators (Muzio et al., *supra.*) and MACH by a second group that published their discovery at the same time (Boldin et al. *Cell* 85:803-815, 1996). According to recently adopted nomenclature, (*Cell* 87:171, 1996) this 35 protein is now called Caspase-8.

- 22 -

The recruitment of Caspase-8 to the receptor complex (via FADD/MORT1) results in activation of the protease activity of Caspase-8, which is required for apoptosis. Accordingly, the novel forms of Caspase-8 described herein (Caspase-8h and Caspase-8i), which lack this domain but retain the ability to bind FADD/MORT1 (via their FADD death effector domains), would effectively compete with full length Caspase-8 for binding to FADD/MORT1 and thereby prevent the cell from undergoing apoptosis.

Caspase-8h and Caspase-8i Contain One or Two Domains that are Homologous to the Death Effector Domain of FADD

The 117 N-terminal amino acids of FADD/MORT1 are capable of triggering apoptosis. Thus, this segment contains the death effector domain (DED) referred to above and shown as striped segments in Fig. 1 (see also Chinnaiyan et al., *supra*). Muzio et al. (*supra*) reported that Caspase-8 (then called FLICE) contains two N-terminal stretches of approximately 60 amino acids that are homologous to the DED of FADD; a search revealed that residues 7-75 and 101-169 of Caspase-8 "matched" the DED of FADD (residues 4-76), sharing 39% identity (55% similarity) and 28% identity (55% similarity), respectively (Muzio et al., *supra*). The remainder of the Caspase-8 protein is highly homologous to the ICE/CED-3 family, particularly in the regions corresponding to the active subunits of ICE (Muzio et al., *supra*).

Tissue Distribution of Caspase-8

Caspase-8 is constitutively expressed in many fetal and adult human tissues (including colon, small intestine, ovary, thymus, spleen, kidney, liver, and lung), but not in the fetal brain (Muzio et al., *supra*). There was a relative increase in the expression of

- 23 -

caspase-8 in peripheral blood leukocytes, which was reported to be consistent with the important role of FAS/APO1-signaling (CD95-signaling) in lymphocyte homeostasis (Nagata and Golstein, *Science* 267:1449-1456, 5 1995).

An Assay for FAS/APO-1 Mediated Apoptosis

An assay for Fas/APO-1 mediated apoptosis can be used in screening assays to identify compounds that increase or decrease apoptosis. The compounds identified 10 using these assays may alter in the level of apoptosis, the activity of the Fas/APO-1 receptor complex, or the activity of the TNF receptor complex by modulating the expression or activity of Caspase-8h or Caspase-8i. Compounds identified in these assays can be used as 15 therapeutic compounds to treat disorders associated with an abnormal rate of apoptosis, abnormal activity of the Fas/APO-1 receptor complex, or abnormal activity of the TNF receptor complex.

Assays of Fas/APO-1 mediated apoptosis generally 20 employ Fas/APO-1-expressing cells and an antibody directed against Fas/APO-1 which, upon binding to Fas/APO-1 receptor initiates apoptosis. The following assay is one example of such an assay.

MCF-7 breast carcinoma cells (approximately 25 2×10^5) are plated onto gridded 35 mm tissue culture dishes. Optionally, the cells can be transfected with DNA that directs the expression of a form of Caspase-8. For example, the cells can be transfected with 0.25 μg of CMV β -gal and either: (1) 1 μg CMV-caspase-8, 30 (2) CMV-caspase-8 and 4 μg CMV-caspase-8h, or (3) CMV-caspase-8i. The transfections are performed in the presence of 20 μl of lipofectin (Gibco/BRL) in 1 ml Optimem for six hours. Twenty-four hours after transfection, the cells are treated with anti-Fas

- 24 -

antibody (CH11, Oncor, Gaithersburg, MD) to induce apoptosis (the amount of antibody required is empirically determined). Forty-two hours after transfection, the cells are fixed with gluteraldehyde, and examined for

5 β -galactosidase activity by staining with X-gal (according to standard and well known procedures). After staining, 200 successfully transfected cells per plate (as indicated by their blue color) are counted and scored as normal or apoptotic (apoptotic cells were small with

10 conspicuous membrane blebbing). By transfecting cells with caspase-8, caspase-8h, or caspase-8i DNA one can examine the effect of the presence of the various forms of Caspase-8 on FAS/APO-1 mediated cell death. This assay allows one to identify compounds which increase or

15 decrease apoptosis by carrying out the assay in the presence and absence of a selected compound and determining whether that compound increases or decreases apoptosis.

Other cell types, for example SHEP cells, can be

20 used in the assay described above. Furthermore, the cells can be those of stably transfected cell lines.

Numerous substances, in addition to the anti-Fas antibody described above, are capable of inducing apoptosis in various cell types and can thus be used in

25 assays of apoptosis. These substances include physiological activators, such as TNF family members, TGF- β , the neurotransmitters glutamate, dopamine, and NMDA (N-methyl-D-aspartate), calcium, and glucocorticoids. Cell death can also be induced when

30 growth factors are withdrawn from the medium in which the cells are cultured. Additional inducers of apoptosis include heat shock, viral infection, bacterial toxins, expression of the oncogenes myc, rel, and E1A, expression of tumor suppressor genes, cytolytic T cells, oxidants,

35 free radicals, gamma and ultraviolet irradiation,

- 25 -

β -amyloid peptide, ethanol, and chemotherapeutic agents such as Cisplatin, doxorubicin, arabinoside, nitrogen mustard, methotrexate, and vincristine.

To assay cell death mediated by the TNF-receptor, a variation of the above-described assay can be used. In this variation, cell death is triggered by administering TNF in place of anti-Fas antibody. This assay can be used to identify compounds which increase or decrease apoptosis by simply carrying out the assay in the presence and absence of selected compounds.

Nucleic Acid Molecules of the Invention

Isolated nucleic acid molecules, as defined above, can be cDNA, genomic DNA, synthetic DNA, or RNA, and can be double-stranded or single-stranded (*i.e.*, either a sense or an antisense strand). Fragments of these molecules, which are also considered within the scope of the invention, can be produced, for example, by the polymerase chain reaction (PCR) or generated by treatment with one or more restriction endonucleases. A ribonucleic acid (RNA) molecule can be produced by *in vitro* transcription.

The nucleic acid molecules of the invention can contain naturally occurring sequences, or sequences that differ from those that occur naturally, but, due to the degeneracy of the genetic code, encode the same polypeptide. In addition, these nucleic acid molecules are not limited to sequences that only encode functional polypeptides, and thus, can include some or all of the non-coding sequences that lie upstream or downstream from a coding sequence.

The nucleic acid molecules of the invention can be synthesized (for example, by phosphoramidite-based synthesis) or obtained from a biological cell, such as the cell of a mammal. Thus, the nucleic acids can be

- 26 -

those of a human, mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, monkey, dog, or cat. Combinations or modifications of the nucleotides within these types of nucleic acids are also encompassed.

5 The isolated nucleic acid molecules of the invention encompass fragments that are not found as such in the natural state. Thus, the invention encompasses recombinant molecules, such as those in which a nucleic acid sequence (for example, a sequence encoding of
10 Caspase-8h or Caspase-8i) is incorporated into a vector (for example, a plasmid or viral vector) or into the genome of a heterologous cell (or the genome of a homologous cell, at a position other than the natural chromosomal location). These circumstances are discussed
15 further below.

 In the event the nucleic acid molecules of the invention encode or act as antisense molecules, they can be used for example, to regulate transcription of the alternate forms of the invention. With respect to
20 regulation of caspase-8h or caspase-8i transcription, such techniques can be used to diagnose and/or treat disorders associated with apoptotic cell death. These nucleic acids will be discussed further in that context.

 In most cases, a DNA sequence encoding Caspase-8h
25 or Caspase-8i will be one which produces Caspase-8h or Caspase-8i mRNA directly, without splicing. Thus, the DNA sequence will be based on the Caspase-8h or Caspase-8i mRNA sequence described herein rather than the caspase-8 genomic sequence.

30 In addition to the nucleotide sequences disclosed herein (see, for example SEQ ID NOS:1 and 3), equivalent forms may be present in other species, and can be identified and isolated by using the nucleotide sequences disclosed herein and standard molecular biological
35 techniques. For example, homologs of caspase-8h or

- 27 -

caspase-8i may be isolated from other organisms by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of amino acid sequences of the alternatively spliced exons.

- 5 Alternatively, the method used to identify human caspase-8h and caspase-8i can be used to isolate homologs from other species. The template for the reaction may be cDNA obtained by reverse transcription of mRNA prepared from, for example, human or non-human cell lines or
- 10 tissues, particularly those known or suspected to express caspase-8. The PCR product may be subcloned and sequenced to ensure that the amplified nucleic acid sequence represents the sequence of caspase-8h or caspase-8i. Once identified, caspase-8h and caspase-8i
- 15 in other species can be used, in turn, to develop animal models for the purpose of drug discovery. Alternatively, these forms of caspase-8 can be used in *in vitro* assays for the purpose of drug discovery.

- The invention also encompasses nucleotide
- 20 sequences that encode mutant Caspase-8h or Caspase-8i, or fragments thereof, that retain one or more functions of Caspase-8h or Caspase-8i, as described herein.

- The invention also encompasses: (a) expression vectors that contain any of the foregoing Caspase-8h or
- 25 Caspase-8i coding sequences and/or their complements (that is, "antisense" sequence); (b) expression vectors that contain Caspase-8h or Caspase-8i coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences; (c)
- 30 expression vectors containing caspase-8h or caspase-8i nucleic acid molecules and heterologous nucleic acid molecules, such as molecules encoding a reporter or marker; and (d) genetically engineered host cells that contain any of the foregoing expression vectors and

- 28 -

thereby express the nucleic acid molecules of the invention in the host cell.

As used herein, regulatory elements include but are not limited to inducible and non-inducible promoters, enhancers, operators and other elements, which are known to those skilled in the art, that drive and regulate gene expression. Such regulatory elements include but are not limited to the cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α -mating factors.

Similarly, the nucleic acid can form part of a hybrid gene encoding additional polypeptide sequences (for example, sequences that function as a marker or reporter) that can be used, for example, to produce a fusion protein (as described further below). Examples of marker or reporter genes include β -lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo^r , G418^r), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding β -galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT). As with many of the standard procedures associated with the practice of the invention, skilled artisans will be aware of additional useful reagents, for example, of additional sequences that can serve the function of a marker or reporter.

The expression systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (for example, *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage

- 29 -

DNA, plasmid DNA or cosmid DNA expression vectors containing the nucleic acid molecules of the invention; yeast (for example, *Saccharomyces* and *Pichia*) transformed with recombinant yeast expression vectors containing the
5 nucleic acid molecules of the invention (preferably containing the nucleic acid sequences of caspase-8h and/or caspase-8i); insect cell systems infected with recombinant virus expression vectors (for example, baculovirus) containing the nucleic acid molecules of the
10 invention; plant cell systems infected with recombinant virus expression vectors (for example, cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression vectors (for example, Ti plasmid) containing caspase-8h and/or
15 caspase-8i nucleotide sequences; or mammalian cell systems (for example, COS, CHO, BHK, 293, VERO, HeLa, MDCK, WI38, and NIH 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (for example, the
20 metallothionein promoter) or from mammalian viruses (for example, the adenovirus late promoter and the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the
25 use intended for the gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of Caspase-8h or Caspase-8i polypeptides for raising antibodies to those proteins, vectors that are
30 capable of directing the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited to, the *E. coli* expression vector pUR278 (Ruther et al., *EMBO J.* 2:1791, 1983), in which the coding sequence of the
35 insert may be ligated individually into the vector in

- 30 -

frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye and Inouye, *Nucleic Acids Res.* 13:3101-3109, 1985; Van Heeke and Schuster, *J. Biol. Chem.* 264:5503-5509, 1989); and the
5 like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by
10 elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica*
15 nuclear polyhydrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The coding sequence of the insert may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed
20 under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of the coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by
25 the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed. (for example, see Smith et al. *J. Virol.* 46:584, 1983; Smith, U.S. Patent No. 4,215,051).

30 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the nucleic acid molecule of the invention may be ligated to an adenovirus transcription/translation control complex, for
35 example, the late promoter and tripartite leader

- 31 -

sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (for example, region E1 or E3) will result in a

5 recombinant virus that is viable and capable of expressing the polypeptide encoded by the nucleic acid molecule of the invention in infected hosts (for example, see Logan and Shenk, *Proc. Natl. Acad. Sci. USA* 81:3655-3659, 1984). Specific initiation signals may also be

10 required for efficient translation of inserted nucleic acid molecules. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate

15 expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the

20 initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of

25 expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., *Methods in Enzymol.* 153:516-544, 1987).

In addition, a host cell strain may be chosen

30 which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (for example, glycosylation) and processing (for example, cleavage) of protein products may be important for the

35 function of the protein. Different host cells have

- 32 -

characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express Caspase-8h or Caspase-8i sequences described above may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (for example, promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which produce Caspase-8h and/or Caspase-8i. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the gene product.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., *Cell* 11:223, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska

- 33 -

and Szybalski, *Proc. Natl. Acad. Sci. USA* 48:2026, 1962), and adenine phosphoribosyltransferase (Lowy, et al., *Cell* 22:817, 1980) genes can be employed in tk⁻, hgp⁺ or ap⁺ cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler, et al., *Proc. Natl. Acad. Sci. USA* 77:3567, 1980; O'Hare, et al., *Proc. Natl. Acad. Sci. USA* 78:1527, 1981); gpt, which confers resistance to mycophenolic acid (Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78:2072, 1981); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al., *J. Mol. Biol.* 150:1, 1981); and hyg⁺, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147, 1984).

Alternatively, any fusion protein may be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (*Proc. Natl. Acad. Sci. USA* 88: 8972-8976, 1991). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni²⁺-nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

30 Polypeptides of the Invention

The Caspase-8h and Caspase-8i polypeptides described herein and fragments, mutants, and truncated forms thereof, including fusion proteins, can be prepared for a variety of uses, including but not limited to the

- 34 -

generation of antibodies, as reagents in diagnostic assays, for the identification of other cellular gene products involved in the regulation of apoptosis, as reagents in assays for screening for compounds that can be used in the treatment of disorders associated with apoptotic cell death, abnormal activity of the Fas/APO-1 receptor, or abnormal activity of the TNF receptor, and as pharmaceutical reagents useful in the treatment of such disorders.

10 The invention encompasses proteins and polypeptides that have one or more of the functions of naturally-occurring Caspase-8h or Caspase-8i. Among the functional attributes of Caspase-8h and Caspase-8i are: the ability to bind FADD/MORT1 and the ability to inhibit cell death associated with activation of the Fas/APO1 receptor. Polypeptides having one or more functions of naturally-occurring Caspase-8h or Caspase-8i can be closely related to Caspase-8h or Caspase-8i. Such polypeptides can be created by functionally equivalent proteins include, but are not limited to, additions or substitutions of amino acid residues within the amino acid sequence encoded by the nucleotide sequences described above (see SEQ ID NOS:1 and 3), but which result in a silent change, thus producing a functionally equivalent gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. Amino acids that are typically considered as providing a conservative substitution for one another are specified in the summary of the invention.

 While random mutations can be made to caspase-8h or caspase-8i DNA (using random mutagenesis techniques well known to those skilled in the art) and the resulting mutant polypeptides tested for activity, site-directed

- 35 -

mutations of these coding sequence can be engineered (using site-directed mutagenesis techniques well known to those skilled in the art) to generate mutant polypeptides with increased function, for example, higher binding
5 affinity for FADD/MORT1, and/or greater ability to inhibit apoptotic cell death.

While the polypeptides of the invention can be chemically synthesized (for example, see Creighton, "Proteins: Structures and Molecular Principles," W.H.
10 Freeman & Co., NY, 1983), large polypeptides, i.e., polypeptides equivalent in size to Caspase-8h, may advantageously be produced by recombinant DNA technology including *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination described
15 herein. In addition, skilled artisans may consult Ausubel et al. ("Current Protocols in Molecular Biology, Vol. I," Green Publishing Associates, Inc., and John Wiley & sons, Inc., NY, 1989), Sambrook et al. ("Molecular Cloning, A Laboratory Manual," Cold Spring
20 Harbor Press, Cold Spring Harbor, NY, 1989), and, particularly for examples of chemical synthesis, Gait, M.J. (Ed. "Oligonucleotide Synthesis," IRL Press, Oxford, 1984), which are incorporated by reference herein in their entirety.

25 Antibodies

The invention also encompasses antibodies that bind Caspase-8h or Caspase-8i. Antibodies that specifically recognize one or more epitopes of these proteins, or fragments thereof are also encompassed by
30 the invention. Such antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic

- 36 -

(anti-Id) antibodies, and epitope-binding fragments of any of the above.

The antibodies of the invention may be used, for example, in the detection of various forms of Caspase-8 in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal amounts of Caspase-8h or Caspase-8i. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes, as described below, for the evaluation of the effect of test compounds on expression and/or activity of Caspase-8h or Caspase-8i. Additionally, such antibodies can be used in conjunction with the gene therapy techniques described below, to, for example, evaluate cells expressing the alternate forms described herein prior to their introduction into the patient. Preferably, the antibodies recognize epitopes of Caspase-8h or Caspase-8i that are unique, i.e., are not present on other forms of Caspase-8 or more distantly related proteins. Accordingly, the antibodies are preferably raised against a peptide sequence present in Caspase-8h or Caspase-8i that is not present in other forms of Caspase-8 (e.g., the various forms of Caspase-8 described by Boldin et al., *supra*).

For the production of antibodies, various host animals may be immunized by injection with a peptide having a sequence that is present in Caspase-8h and/or Caspase-8i. Such host animals may include but are not limited to rabbits, mice, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole

- 37 -

limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein (*Nature* 256:495-497, 1975; and U.S. Patent No. 4,376,110), the human B cell hybridoma technique (Kosbor et al., *Immunology Today* 4:72, 1983; Cole et al., *Proc. Natl. Acad. Sci. USA* 80:2026-2030, 1983), and the EBV-hybridoma technique (Cole et al., "Monoclonal Antibodies And Cancer Therapy," Alan R. Liss, Inc., pp. 77-96, 1985). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated *in vitro* or *in vivo*. Production of high titers of mAbs *in vivo* makes this the presently preferred method of production.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., *Proc. Natl. Acad. Sci. USA*, 81:6851-6855, 1984; Neuberger et al., *Nature*, 312:604-608, 1984; Takeda et al., *Nature*, 314:452-454, 1985) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

- 38 -

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, *Science* 242:423-426, 1988; Huston et al., *Proc. Natl. Acad. Sci. USA* 85:5879-5883, 1988; and
5 Ward et al., 1989, *Nature* 334:544-546, 1989) can be adapted to produce single chain antibodies against caspase-8h or caspase-8i gene products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid
10 bridge, resulting in a single chain polypeptide.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments which can be produced by pepsin
15 digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., *Science*, 246:1275-1281, 1989) to allow rapid and easy
20 identification of monoclonal Fab fragments with the desired specificity.

These antibodies can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" Caspase-8h or Caspase-8i, using techniques well known to those
25 skilled in the art. (See, for example, Greenspan and Bona, *FASEB J.* 7(5):437-444, 1993; and Nissinoff, *J. Immunol.* 147(8):2429-2438, 1991). Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in diagnostic regimens to detect disorders
30 associated with apoptotic cell death.

Antibodies can be humanized by methods known in the art. For example, monoclonal antibodies with a desired binding specificity can be commercially humanized (Scotgene, Scotland; Oxford Molecular, Palo Alto, CA).
35 Fully human antibodies, such as those expressed in

- 39 -

transgenic animals are also features of the invention (Green et al., *Nature Genetics* 7:13-21, 1994; see also U.S. Patents 5,545,806 and 5,569,825, both of which are hereby incorporated by reference).

5 The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific caspase-8h or caspase-8i nucleotide sequence or antibody reagent described herein, which may be conveniently used, for example, in clinical
10 settings, to diagnose patients exhibiting symptoms of the disorders described below.

Transgenic Animals

In another embodiment, the present invention relates to non-human, transgenic animals having cells
15 that express the nucleic acid molecules of the invention. Preferably, the animals express Caspase-8h and/or Caspase-8i (e.g., encoded by a gene which produces Caspase-8h or Caspase-8i mRNA without splicing). Such transgenic animals represent a model system for the study
20 of disorders that are caused by or exacerbated either by excessive or insufficient apoptotic cell death, and for the development of therapeutic agents that modulate the expression or activity of the forms of Caspase-8 described herein. As defined above, animals such as
25 mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, and non-human primates, for example, baboons, monkeys, and chimpanzees may be used to generate these transgenic animals.

Preferably, the transgenic animals of the present
30 invention are produced by introducing a nucleic acid molecule of the invention into single-celled embryos so that the DNA is stably integrated into the DNA of germ-line cells in the mature animal, and inherited in a Mendelian fashion.

- 40 -

However, any technique known in the art may be used to introduce the transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (see, for example, U.S. Patent No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten et al., 1985, *Proc. Natl. Acad. Sci., USA* 82:6148-6152); gene targeting in embryonic stem cells (Thompson et al., 1989, *Cell* 56:313-321); electroporation of embryos (Lo, 1983, *Mol Cell. Biol.* 3:1803-1814); and sperm-mediated gene transfer (Lavitrano et al., 1989, *Cell* 57:717-723); etc. For a review of such techniques, see Gordon, 1989, *Transgenic Animals*, *Intl. Rev. Cytol.* 115:171-229. Skilled artisans may obtain additional guidance from, for example: Hogan et al. "Manipulating the Mouse Embryo" (Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1986; Krimpenfort et al., *Bio/Technology* 9:86, 1991; Palmiter et al., *Cell* 41:343, 1985; Kraemer et al., "Genetic Manipulation of the Early Mammalian Embryo" (Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1985; Hammer et al., *Nature* 315:680, 1985; Purcel et al., *Science*, 244:1281, 1986; Wagner et al., U.S. Patent 5,175,385; and Krimpenfort et al., U.S. Patent No. 5,175,384 (the latter two publications are hereby incorporated by reference).

The present invention provides for transgenic animals that carry the Caspase-8-related transgene of the invention in all their cells, as well as animals which carry the transgene in some, but not all their cells, that is, the invention provides for mosaic animals. The transgene may be integrated as a single transgene or in concatamers, for example, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al.

- 41 -

(*Proc. Natl. Acad. Sci. USA* 89:6232-6236, 1992). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

When it is desired that the caspase-8h or caspase-8i transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous caspase-8 gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous caspase-8 gene. A transgene may also be selectively introduced into a particular cell type, thus inactivating or "knocking out" the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (*Science* 265:103-106, 1994). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

The level of mRNA expression of the transgene in the tissues of the transgenic animals may be assessed using techniques which include but are not limited to Northern blot or RNase protection analysis of tissue samples obtained from the animal.

Use of the Nucleic Acids, Polypeptides, and Antibodies of the Invention in the Diagnosis and Treatment of Disorders associated with Apoptotic Cell Death

As described below, the nucleic acids, polypeptides, antibodies, and other reagents of the invention can be used in the diagnosis and treatment of

- 42 -

disorders associated with apoptotic cell death. In general, disorders associated with increased cell death are those in which the expression or activity of Caspase-8h and/or Caspase-8i may be insufficient. Thus, 5 these disorders can be treated by enhancing the expression or activity of Caspase-8h and/or Caspase-8i. Conversely, disorders associated with decreased cell death are those in which expression or activity of Caspase-8h and/or Caspase-8i is excessive, and which 10 would respond to treatment regimes in which expression or activity of these genes is inhibited. The disorders amenable to treatment will first be briefly reviewed and a discussion of therapeutic applications will follow (see, for example, "Formulations and Use").

15 Skilled artisans may consult Thompson (Science 267:1456-1462, 1995) for a more detailed discussion of the disorders associated with apoptotic cell death.

Whether a Disorder is Mediated by the Expression of Caspase-8h or Caspase-8i

20 If one can determine whether a disorder is associated with apoptotic cell death, and whether that cell death is influenced by expression of the forms of Caspase-8 disclosed herein, it should be possible to determine whether that disorder can be diagnosed or 25 treated with the nucleic acid, polypeptide, or antibody molecules of the invention. A disorder in which there is either insufficient or excessive cell death may be studied by determining whether caspase-8h or caspase-8i are either overexpressed or underexpressed in the 30 affected tissue. The expression levels can be compared from tissue to tissue within a single patient, or between tissue samples obtained from a patient that is ill and one or more patients who are well. If it is determined that either Caspase-8h, Caspase-8i, or both are either 35 overexpressed or underexpressed, it can be said that the

- 43 -

disorder should be amenable to one or more of the treatment methods disclosed herein.

Diagnostic methods in which caspase-8h and caspase-8i are detected in a biological sample can be
5 carried out, for example, by amplifying the nucleic acid molecules within the sample by PCR (the experimental embodiment set forth in Mullis, K.B., 1987, U.S. Patent No. 4,683,202), followed by the detection of the
10 amplified molecules using techniques well known to those of skill in the art. For example, for detection of the amplified product, the nucleic acid amplification may be performed using radioactively or non-radioactively labeled nucleotides. Alternatively, enough amplified
15 product may be made such that the product may be visualized by standard ethidium bromide staining or by utilizing any other suitable nucleic acid staining method. The resulting amplified sequences can be compared to those which were obtained either from a tissue that is not affected by the disorder, from a
20 person who is well, or that were obtained from the patient before the disorder developed.

The level of expression of Caspase-8h and Caspase-8i can also be assayed by detecting and measuring transcription. For example, RNA from a cell type or
25 tissue that is known, or suspected to express these forms of Caspase-8, may be isolated and tested utilizing the PCR techniques described above.

The analysis of cells taken from culture may be a necessary step in the assessment of cells to be used as
30 part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of Caspase-8h and Caspase-8i. Such analyses may reveal both quantitative and qualitative aspects of the expression pattern of these forms of Caspase-8,
35 including activation or inactivation of their expression.

- 44 -

Where a sufficient quantity of the appropriate cells can be obtained, standard Northern blot or RNase protection analyses can be performed to determine the level of mRNA encoding the various forms of Caspase-8, particularly Caspase-8h and Caspase-8i.

It is also possible to base diagnostic assays and screening assays for therapeutic compounds on detection of Caspase-8h polypeptide or Caspase-8i polypeptide. Such assays for Caspase-8h polypeptide or Caspase-8i polypeptide, or peptide fragments thereof will typically involve incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells which have been incubated in cell culture, in the presence of a detectably labeled antibody capable of identifying these gene products (or peptide fragments thereof), and detecting the bound antibody by any of a number of techniques well-known in the art.

The biological sample may be brought in contact with and immobilized onto a solid phase support or carrier such as nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles, or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled antibody or fusion protein. The solid phase support may then be washed with the buffer a second time to remove unbound antibody or fusion protein. The amount of bound label on solid support may then be detected by conventional means.

By "solid phase support or carrier" is intended any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or

- 45 -

insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, 5 the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those 10 skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

The binding activity of a given lot of anti-Caspase-8h or anti-Caspase-8i antibody or fusion 15 proteins containing these polypeptides may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

20 With respect to antibodies, one of the ways in which the antibody of the instant invention can be detectably labeled is by linking it to an enzyme for use in an enzyme immunoassay (EIA) (Voller, A., "The Enzyme Linked Immunosorbent Assay (ELISA)", 1978, Diagnostic 25 Horizons 2:1-7, Microbiological Associates Quarterly Publication, Walkersville, MD; Voller, A. et al., 1978, *J. Clin. Pathol.* 31:507-520; Butler, J.E., 1981, *Meth. Enzymol.* 73:482-523; Maggio, E. (ed.), "Enzyme Immunoassay," CRC Press, Boca Raton, FL, 1980; Ishikawa, 30 E. et al., (eds.), "Enzyme Immunoassay," Kaku Shoin, Tokyo, 1981). The enzyme which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by 35 spectrophotometric, fluorimetric or by visual means.

- 46 -

- Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.
- 10 The detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.
- 15 Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect Caspase-8h and Caspase-8i through the use of a radioimmunoassay (RIA)
- 20 (see, for example, Weintraub, B., "Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques," The Endocrine Society, March, 1986, which is incorporated by reference herein). The radioactive isotope can be detected by such means as the
- 25 use of a gamma counter or a scintillation counter or by autoradiography.
- It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length,
- 30 its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

- 47 -

The antibody can also be detectably labeled using fluorescence emitting metals such as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as

5 diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then

10 determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

15 Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent

20 reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

Still further, the invention encompasses methods

25 and compositions for the treatment of the disorders described above, and any others that are found to be associated with apoptotic cell death. Such methods and compositions are capable of modulating the level of expression of caspase-8h or caspase-8i and/or the level

30 of activity of the gene products.

Numerous ways of altering the expression or activity of the polypeptides of the invention are known to skilled artisans. For example, living cells can be transfected *in vivo* with the nucleic acid molecules of

35 the invention (or transfected *in vitro* and subsequently

- 48 -

administered to the patient). For example, cells can be transfected with plasmid vectors by standard methods including, but not limited to, liposome- polybrene-, or DEAE dextran-mediated transfection (see, e.g., Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413, 1987; Ono et al., *Neurosci. Lett.* 117:259, 1990; Brigham et al., *Am. J. Med. Sci.* 298:278, 1989), electroporation (Neumann et al., *EMBO J.* 7:841, 1980), calcium phosphate precipitation (Graham et al., *Virology* 52:456, 1973; Wigler et al., *Cell* 14:725, 1978; Felgner et al., *supra*) microinjection (Wolff et al., *Science* 247:1465, 1990), or velocity driven microprojectiles ("biolistics").

These methods may be employed to mediate therapeutic application of the molecules of the invention. For example, antisense nucleic acid therapies or ribozyme approaches may be used to inhibit utilization of caspase-8h and/or caspase-8i mRNA; triple helix approaches may also be successful in inhibiting transcription of various forms of Caspase-8. Antisense approaches involve the design of oligonucleotides (either DNA or RNA) that are complementary to the mRNA molecules of the invention. The antisense oligonucleotides will bind to the complementary mRNA transcripts and prevent translation. Antisense oligonucleotides must be specific for the mRNA of interest. Accordingly, oligonucleotides spanning the splice junctions are especially preferred. For example, the following oligonucleotides are suitable for specifically binding caspase-8h mRNA: tttgtccaaagtctttgctgaatt (SEQ ID NO:7). The following oligonucleotides are suitable for specifically binding caspase-8i mRNA: tggagatttcctcttgcaaaagaaactta (SEQ ID NO:8); gatagagcatttgaggatttcc (SEQ ID NO:9); and cttttcagggtaaactcaattctg (SEQ ID NO:10).

Absolute complementarity, although preferred, is not required. A sequence "complementary" to a portion of

- 49 -

an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation than oligonucleotides that are complementary to 5'- or 3'- untranslated sequence, but should be used in accordance with the instant invention. The antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects, the oligonucleotide is at least 10 nucleotides, preferably at least 17 nucleotides, more preferably at least 25 nucleotides or most preferably at least 50 nucleotides.

Regardless of the choice of target sequence, it is preferred that *in vitro* studies are first performed to quantitate the ability of the antisense oligonucleotide to inhibit gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained

- 50 -

using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleotide sequence of the oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.

The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (for example, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, for example, Letsinger et al., *Proc. Natl. Acad. Sci. USA* 86:6553-6556, 1989; Lemaitre et al., *Proc. Natl. Acad. Sci. USA* 84:648-652, 1987; PCT Publication No. WO88/09810, published December 15, 1988) or the blood-brain barrier (see, for example, PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, for example, Krol et al., *BioTechniques* 6:958-976, 1988) or intercalating agents (see, for example, Zon, *Pharm. Res.* 5:539-549, 1988). To this end, the oligonucleotide may be conjugated to another molecule, for example, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, and the like.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine,

- 51 -

5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic 10 acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, 15 (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

20 In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a 25 phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an α -anomeric oligonucleotide. An α -anomeric oligonucleotide forms specific double-stranded 30 hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier et al., 1987, *Nucl. Acids Res.* 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., *Nucl. Acids Res.* 15:6131-6148, 1987), or a

- 52 -

chimeric RNA-DNA analogue (Inoue et al., *FEBS Lett.* 215:327-330, 1987).

Oligonucleotides of the invention may be synthesized by standard methods known in the art, for example, by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (*Nucl. Acids Res.* 16:3209, 1988), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., *Proc. Natl. Acad. Sci. USA* 85:7448-7451, 1988), etc.

The antisense molecules should be delivered to cells which express caspase-8h and/or caspase-8i *in vivo*. A number of methods have been developed for delivering antisense DNA or RNA to cells; for example, antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (for example, antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.

However, it is often difficult to achieve intracellular concentrations of the antisense sufficient to suppress translation of endogenous mRNAs. Therefore a preferred approach utilizes a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong pol III or pol II promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous caspase-8h and/or caspase-8i transcripts and thereby prevent translation of the caspase-8h and/or caspase-8i mRNA. For example, a vector can be introduced *in vivo* such that

- 53 -

it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such
5 vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any
10 promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, *Nature* 290:304-310, 1981), the promoter contained in the
15 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell* 22:787-797, 1980), the herpes thymidine kinase promoter (Wagner et al., *Proc. Natl. Acad. Sci. USA* 78:1441-1445, 1981), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature* 296:39-42,
20 1982), etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site; for example, the choroid plexus or hypothalamus. Alternatively, viral vectors can be used
25 which selectively infect the desired tissue; (for example, for brain, herpesvirus vectors may be used), in which case administration may be accomplished by another route (for example, systemically).

Methods of designing antisense nucleic acids and
30 introducing them into host cells have been described in, for example, Weinberg et al. (U.S. Patent 4,740,463; hereby incorporated by reference).

Alternatively, the nucleic acid molecules of the invention can be administered so that expression of the
35 caspase-8h and/or caspase-8i occurs in tissues where it

- 54 -

does not normally occur, or is enhanced in tissues where it is normally expressed. This application can be used, for example, to suppress apoptotic cell death and thereby treat disorders in which cellular populations are

5 diminished, such as those described below as "disorders associated with diminished cell survival." Preferably, the therapeutic nucleic acid (or recombinant nucleic acid construct) is applied to the site where cells are at risk of dying by apoptosis, to the tissue in the larger

10 vicinity, or to the blood vessels supplying these areas.

Ideally, the production of a polypeptide that is a form of Caspase-8 lacking the ICE/CED3 protease domain (e.g., Caspase-8h or Caspase-8i), by any gene therapy approach described herein will result in a cellular level

15 of expression that is at least equivalent to the normal, cellular level of expression of these genes. Skilled artisans will recognize that these therapies can be used in combination with more traditional therapies, such as surgery, radiotherapy, or chemotherapy. Accordingly,

20 and as described below, the invention features therapeutic compositions that contain the nucleic acid molecules, polypeptides, and antibodies of the invention, as well as compounds that are discovered, as described below, to affect them.

25 Therapeutic Compositions

The nucleic acid molecules encoding Caspase-8h and Caspase-8i, the polypeptides themselves, antibodies that specifically bind Caspase-8h and/or Caspase-8i and compounds that affect the expression or activity of

30 Caspase-8h or Caspase-8i can be administered to a patient at therapeutically effective doses to treat or ameliorate disorders associated with apoptotic cell death. A therapeutically effective dose refers to the dose that is

- 55 -

sufficient to result in amelioration of symptoms of disorders associated with apoptotic cell death.

Effective Dose

Toxicity and therapeutic efficacy of a given compound can be determined by standard pharmaceutical procedures, using either cells in culture or experimental animals to determine the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to unaffected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (that is, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.

- 56 -

Levels in plasma may be measured, for example, by high performance liquid chromatography.

Formulations and Use

Pharmaceutical compositions for use in accordance
5 with the present invention may be formulated in
conventional manner using one or more physiologically
acceptable carriers or excipients.

Thus, the compounds and their physiologically
acceptable salts and solvates may be formulated for
10 administration by inhalation or insufflation (either
through the mouth or the nose) or oral, buccal,
parenteral or rectal administration.

For oral administration, the pharmaceutical
compositions may take the form of, for example, tablets
15 or capsules prepared by conventional means with
pharmaceutically acceptable excipients such as binding
agents (for example, pregelatinised maize starch,
polyvinylpyrrolidone or hydroxypropyl methylcellulose);
fillers (for example, lactose, microcrystalline cellulose
20 or calcium hydrogen phosphate); lubricants (for example,
magnesium stearate, talc or silica); disintegrants (for
example, potato starch or sodium starch glycolate); or
wetting agents (for example, sodium lauryl sulphate).
The tablets may be coated by methods well known in the
25 art. Liquid preparations for oral administration may
take the form of, for example, solutions, syrups or
suspensions, or they may be presented as a dry product
for constitution with water or other suitable vehicle
before use. Such liquid preparations may be prepared by
30 conventional means with pharmaceutically acceptable
additives such as suspending agents (for example,
sorbitol syrup, cellulose derivatives or hydrogenated
edible fats); emulsifying agents (for example, lecithin
or acacia); non-aqueous vehicles (for example, almond

- 57 -

oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (for example, methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and
5 sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may
10 take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray
15 presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the
20 dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

25 The compounds may be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, for example, in ampoules or in multi-dose containers, with an
30 added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder

- 58 -

form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, 5 for example, containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be 10 administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange 15 resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The 20 pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

The therapeutic compositions of the invention can also contain a carrier or excipient, many of which are 25 known to skilled artisans. Excipients which can be used include buffers (for example, citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins (for example, serum albumin), EDTA, sodium 30 chloride, liposomes, mannitol, sorbitol, and glycerol. The nucleic acids, polypeptides, antibodies, or modulatory compounds of the invention can be administered by any standard route of administration. For example, administration can be parenteral, intravenous, 35 subcutaneous, intramuscular, intracranial, intraorbital,

- 59 -

ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, transmucosal, or oral. The modulatory compound can be formulated in various ways, according to the corresponding route of

5 administration. For example, liquid solutions can be made for ingestion or injection; gels or powders can be made for ingestion, inhalation, or topical application. Methods for making such formulations are well known and can be found in, for example, "Remington's Pharmaceutical
10 Sciences. It is expected that the preferred route of administration will be intravenous.

It is well known in the medical arts that dosages for any one patient depend on many factors, including the general health, sex, weight, body surface area, and age
15 of the patient, as well as the particular compound to be administered, the time and route of administration, and other drugs being administered concurrently.

Dosages for the polypeptides and antibodies of the invention will vary, but a preferred dosage for
20 intravenous administration is approximately 0.01 mg to 100 mg/ml blood volume. Determination of the correct dosage within a given therapeutic regime is well within the abilities of one of ordinary skill in the art of pharmacology. Skilled artisans will be aided in their
25 determination of an adequate dosage by previous studies. For example, Abraham et al. (*J. Amer. Med. Assoc.* 273:934-941, 1995) administered TNF- α monoclonal antibody (TNF- α -MAb) at doses ranging from 1 to 15 mg/kg. The antibody was well tolerated by all patients, even though
30 they developed human antimurine antibodies; no serum sickness-like reactions, adverse skin reactions, or systemic allergic reactions developed. Similarly, Rankin et al. (*Br. J. Rheumatol.* 34:334-342, 1995) administered a single intravenous dose of 0.1, 1.0, or 10 mg/kg of an
35 engineered human antibody, CDP571, which neutralizes

- 60 -

human TNF- α . Both studies describe in detail how to evaluate patients who have been treated with antibodies.

5 Identification of Compounds that mediate
 Oligomerization between the Fas/APO-1 or TNF
 receptor complexes and Caspase-8h and/or
 Caspase-8i

 It has been shown previously (see Background of the Invention) that apoptosis is induced by the formation of a specific complex of polypeptides, that includes
10 Caspase-8, when either the Fas/APO-1 or TNF receptors are activated. Binding of Caspase-8h or Caspase-8i to these receptor complexes in place of forms of Caspase-8 having an ICE/CED-3 domain may inhibit apoptosis. Therefore, apoptosis can be inhibited within a cell that contains
15 compounds that specifically promote interaction between Caspase-8h and/or Caspase-8i and proteins within the receptor complexes described above. Accordingly, the invention features a method for treating a patient who is suffering from an abnormally high rate of apoptotic cell
20 death by administering to the patient a ligand that mediates oligomerization between proteins in either the Fas/APO-1 or TNF receptor complexes.

 The invention also features methods for screening compounds to identify compounds which increase or
25 decrease the interaction between either the Fas/APO-1 receptor complex of the TNF receptor complex and Caspase-8h or Caspase-8i. One suitable assay for determining whether Caspase-8h or Caspase-8i or some other form of Caspase-8 has associated with the Fas/APO-1 complex is an
30 immuprecipitation assay. A suitable immunoprecipitation assay is described by Kischkel et al. (EMBO J. 14:5579, 1995). Anti-Caspase-8 antibodies can be used to detect various forms of Caspase-8, which can be distinguished by their size. Such assays can be performed in the presence
35 and absence of selected compounds to identify those which

- 61 -

increase or decrease association between a Caspase-8 and the receptor complex.

Recently, compounds that can penetrate the cell membrane were devised and shown to be capable of
5 controlling the intracellular oligomerization of specific proteins. More specifically, ligands were used to induce intracellular oligomerization of cell surface receptors that lacked their transmembrane and extracellular regions but that contained intracellular signaling domains.
10 Spencer et al. (*Science* 262:1019-1024, 1993) reported that addition of these ligands to cells in culture resulted in signal transmission and specific target gene activation. Further, these investigators proposed the use of these ligands "wherever precise control of a
15 signal transduction pathway is desired." For further guidance in the use of synthetic ligands to induce dimerization of proteins, see Belshaw et al. (*Proc. Natl. Acad. Sci. USA* 93:4604-4607). This approach can be used to induce intracellular oligomerization of Caspase-8.

20 Identification of Compounds that Modulate the Expression or Activity of Caspase-8h or Caspase-8i

Isolation of the nucleic acid molecules described above (i.e. those encoding Caspase-8h and Caspase-8i) also facilitates the identification of compounds that can
25 increase or decrease the expression of these molecules *in vivo*. To discover such compounds, cells that express Caspase-8h and/or Caspase-8i are cultured, exposed to a test compound (or a mixture of test compounds), and the level of Caspase-8h and/or Caspase-8i expression or
30 activity is compared with the level of expression or activity in cells that are otherwise identical but that have not been exposed to the test compound(s). Many standard quantitative assays of gene expression can be utilized in this aspect of the invention. Examples of
35 these assays are provided below.

- 62 -

In order to identify compounds that modulate expression of Caspase-8h or Caspase-8i (or homologous genes) the candidate compound(s) can be added at varying concentrations to the culture medium of cells that
5 express Caspase-8h or Caspase-8i (or their homologue), as described above. These compounds can include small molecules, polypeptides, and nucleic acids. The expression of the caspases is then measured, for example, by Northern blot PCR analysis or RNase protection
10 analyses using a nucleic acid molecule of the invention as a probe. The level of expression in the presence of the candidate molecule, compared with the level of expression in its absence, will indicate whether or not the candidate molecule alters the expression of
15 Caspase-8h or Caspase-8i.

Similarly, compounds that modulate the expression of the polypeptides of the invention can be identified by carrying out the assay described above and then performing a Western blot analysis using antibodies that
20 bind Caspase-8h or Caspase-8i.

The test compounds, by altering the expression of particular isoforms of Caspase-8, will alter the ratio of Caspase-8 to Caspase-8h or Caspase-8i, or both. This, in turn, will alter the likelihood that the cell in which
25 these molecules are expressed will undergo apoptosis. For example, if the test compound decreases the expression of Caspase-8h or Caspase-8i relative to the expression of Caspase-8, the signal generated by binding the Fas/APO or p55 receptors will be transduced, and the
30 cell will respond by activating the apoptotic pathway. In contrast, if the test compound increases the expression of Caspase-8h or Caspase-8i relative to the expression of Caspase-8, the signal generated by binding the Fas/APO or p55 receptors will not be transduced
35 (because the Caspase-8h and Caspase-8i isoforms lack the

- 63 -

cysteine protease domain of the enzyme) and the cell will not undergo apoptosis. Thus, compounds identified in this way can be used as agents to control apoptosis and, in particular, as therapeutic agents for the treatment of various disorders associated with apoptosis (described above).

Compounds which alter and activity (e.g., Fas/APO-1 receptor binding, TNF receptor binding, or apoptosis inhibition) of Caspase-8h or Caspase-8i can be identified using the oligomerization and apoptosis assays described in detail above.

Deposit Information

Two plasmids, cp81 and cp220, bearing cDNA encoding Caspase-8h and Caspase-8i respectively, were deposited with the American Type Culture Collection (12301 Parklawn Drive, Rockville, MD 20852-1776) on February 13, 1997. Plasmid cp81 was assigned accession number 97877, and plasmid cp220 was assigned accession number 97878.

The subject cultures have been deposited under conditions that assure that access to the cultures will be available during the pendency of the patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under CFR 1.14 and 35 USC 122. The deposits are available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny, are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

Further, the subject culture deposits will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of

- 64 -

Microorganisms, i.e., they will be stored with all the care necessary to keep them viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposits, 5 and in any case, for a period of at least 30 (thirty) years after the date of deposit or for the enforceable life of any patent which may issue disclosing the cultures plus five years after the last request for a sample from the deposit. The depositor acknowledges the 10 duty to replace the deposits should the depository be unable to furnish a sample when requested, due to the condition of the deposits. All restrictions on the availability to the public of the subject culture deposits will be irrevocably removed upon the granting of 15 a patent disclosing them.

Additional embodiments are within the following claims.

-65-

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Millennium Pharmaceuticals, Inc.
- (ii) TITLE OF THE INVENTION: NUCLEIC ACIDS ENCODING CASPASE-8H AND CASPASE-8I (as amended)
- (iii) NUMBER OF SEQUENCES: 12
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Fish & Richardson, P.C.
 - (B) STREET: 225 Franklin Street
 - (C) CITY: Boston
 - (D) STATE: MA
 - (E) COUNTRY: US
 - (F) ZIP: 02110-2804
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: Windows95
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: PCT/US98/-----
 - (B) FILING DATE: 27-FEB-1998
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 08/807,200
 - (B) FILING DATE: 27-FEB-1997
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Meiklejohn, Ph.D., Anita L.
 - (B) REGISTRATION NUMBER: 35,283
 - (C) REFERENCE/DOCKET NUMBER: 07334/021WO1
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 617-542-5070
 - (B) TELEFAX: 617-542-8906
 - (C) TELEX: 200154

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1330 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGGACTTCA	GCAGAAATCT	TTATGATATT	GGGGAACAAC	TGGACAGTGA	AGATCTGGCC	60
TCCCTCAAGT	TCCTGAGCCT	GGACTACATT	CCGCAAAGGA	AGCAAGAACC	CATCAAGGAT	120
GCCTTGATGT	TATTCCAGAG	ACTCCAGGAA	AAGAGAATGT	TGGAGGAAAG	CAATCTGTCC	180
TTCCTGAAGG	AGCTGCTCTT	CCGAATTAAT	AGACTGGATT	TGCTGATTAC	CTACCTAAAC	240
ACTAGAAAGG	AGGAGATGGA	AAGGGAACCT	CAGACACCAG	GCAGGGCTCA	AATTTCTGCC	300
TACAGGGTCA	TGCTCTATCA	GATTTTCAGAA	GAAGTGAGCA	GATCAGAATT	GAGGTCTTTT	360
AAGTTTCTTT	TGCAAGAGGA	AATCTCCAAA	TGCAAACCTGG	ATGATGACAT	GAACCTGCTG	420
GATATTTTCA	TAGAGATGGA	GAAGAGGGTC	ATCCTGGGAG	AAGGAAAGTT	GGACATCCCTG	480
AAAAGAGTCT	GTGCCCAAAT	CAACAAGAGC	CTGCTGAAGA	TAATCAACGA	CTATGAAGAA	540
TTCAGGAAAG	ACTTTGGACA	AAGTTTACCA	AATGAAAAGC	AAACCTCGGG	GATACTGTCT	600
GATCATCAAC	AATCACAATT	TTGCAAAGC	ACGGGAGAAA	GTGCCCAAAC	TTCACAGCAT	660
TAGGGACAGG	AATGGAACAC	ACTTGGATGC	AGGGGCTTTG	ACCACGACCT	TTGAAGAGCT	720
TCATTTTGAG	ATCAAGCCCC	ACGATGACTG	CACAGTAGAG	CAAATCTATG	AGATTTTGAA	780
AATCTACCAA	CTCATGGACC	ACAGTAACAT	GGACTGCTTC	ATCTGCTGTA	TCCTCTCCCA	840

-66-

TGGAGACAAG	GGCATCATCT	ATGGCACTGA	TGGACAGGAG	GCCCCCATCT	ATGAGCTGAC	900
ATCTCAGTTC	ACTGGTTTGA	AGTGCCCTTC	CCTTGCTGGA	AAACCCAAAG	TGTTTTTTAT	960
TCAGGCTTGT	CAGGGGGATA	ACTACCAGAA	AGGTATACCT	GTTGAGACTG	ATTCAGAGGA	1020
GCAACCCTAT	TTAGAAATGG	ATTTATCATC	ACCTCAAACG	AGATATATCC	CGGATGAGGC	1080
TGACTTTCTG	CTGGGGATGG	CCACTGTGAA	TAACTGTGTT	TCCTACCGAA	ACCCTGCAGA	1140
GGGAACCTGG	TACATCCAGT	CACCTTGCCA	GAGCCTGAGA	GAGCGATGTC	CTCGAGGCGA	1200
TGATATTCTC	ACCATCCTGA	CTGAAGTGAA	CTATGAAGTA	AGCAACAAGG	ATGACAAGAA	1260
AAACATGGGG	AAACAGATGC	CTCAGCCTAC	TTTCACACTA	AGAAAAAAAC	TTGTCTTCCC	1320
TTCTGATTGA						1330

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 220 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Asp	Phe	Ser	Arg	Asn	Leu	Tyr	Asp	Ile	Gly	Glu	Gln	Leu	Asp	Ser
1				5				10					15		
Glu	Asp	Leu	Ala	Ser	Leu	Lys	Phe	Leu	Ser	Leu	Asp	Tyr	Ile	Pro	Gln
		20						25					30		
Arg	Lys	Gln	Glu	Pro	Ile	Lys	Asp	Ala	Leu	Met	Leu	Phe	Gln	Arg	Leu
		35						40					45		
Gln	Glu	Lys	Arg	Met	Leu	Glu	Glu	Ser	Asn	Leu	Ser	Phe	Leu	Lys	Glu
		50						55				60			
Leu	Leu	Phe	Arg	Ile	Asn	Arg	Leu	Asp	Leu	Leu	Ile	Thr	Tyr	Leu	Asn
		65						70				75			80
Thr	Arg	Lys	Glu	Glu	Met	Glu	Arg	Glu	Leu	Gln	Thr	Pro	Gly	Arg	Ala
				85				90						95	
Gln	Ile	Ser	Ala	Tyr	Arg	Val	Met	Leu	Tyr	Gln	Ile	Ser	Glu	Glu	Val
			100					105					110		
Ser	Arg	Ser	Glu	Leu	Arg	Ser	Phe	Lys	Phe	Leu	Leu	Gln	Glu	Glu	Ile
		115						120				125			
Ser	Lys	Cys	Lys	Leu	Asp	Asp	Met	Asn	Leu	Leu	Asp	Ile	Phe	Ile	
		130						135				140			
Glu	Met	Glu	Lys	Arg	Val	Ile	Leu	Gly	Glu	Gly	Lys	Leu	Asp	Ile	Leu
				150				155						160	
Lys	Arg	Val	Cys	Ala	Gln	Ile	Asn	Lys	Ser	Leu	Leu	Lys	Ile	Ile	Asn
				165				170						175	
Asp	Tyr	Glu	Glu	Phe	Ser	Lys	Asp	Phe	Gly	Gln	Ser	Leu	Pro	Asn	Glu
				180				185					190		
Lys	Gln	Thr	Ser	Gly	Ile	Leu	Ser	Asp	His	Gln	Gln	Ser	Gln	Phe	Cys
		195						200				205			
Lys	Ser	Thr	Gly	Glu	Ser	Ala	Gln	Thr	Ser	Gln	His				
		210					215				220				

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1286 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGGA	CTTCA	GCAGAA	TCTT	TTATGA	TATT	GGGGA	ACAAC	TGGAC	AGTGA	AGATCT	TGGCC	60
TCCCT	CAAGT	TCCTG	AGCCT	GGACT	ACATT	CCGCA	AAGGA	AGCAAG	AACC	CATCA	AGGAT	120
GCCTT	GATGT	TATTC	CAGAG	ACTCC	AGGAA	AAGAA	ATGTT	TGGAG	GAAAG	CAATCT	GTCC	180
TTCTG	AAGG	AGCTG	CTCTT	CCGAAT	TAAAT	AGACT	GGATT	TGCTG	ATTAC	CTACCT	TAAAC	240
ACTTA	AGTTT	CTTTT	GCAAG	AGGAA	ATCTC	CAAAT	GCTCT	ATCAG	ATTTC	AGAAG	AAGTG	300

-67-

```

AGCAGATCAG AATTGAGTTT ACCCTGAAAA GAGTCTGTGC CCAAATCAAC AAGAGCCTGC 360
TGAAGATAAT CAACGACTAT GAAGAATTCA GCAAAGAGAG AAGCAGCAGC CTTGAAGGAA 420
GTCCTGATGA ATTTTCAAAT GGGGAGGAGT TGTGTGGGGT AATGACAATC TCGGACTCTC 480
CAAGAGAACA GGATAGTGAA TCACAGACTT TGGACAAAGT TTACCAAATG AAAAGCAAAC 540
CTCGGGGATA CTGTCTGATC ATCAACAATC ACAATTTTGC AAAAGCACGG GAGAAAGTGC 600
CCAAACTTCA CAGCATTAGG GACAGGAATG GAACACACTT GGATGCAGGG GCTTTGACCA 660
CGACCTTTGA AGAGCTTCAT TTTGAGATCA AGCCCCACGA TGA CTGCACA GTAGAGCAAA 720
TCTATGAGAT TTTGAAAATC TACCAACTCA TGGACCACAG TAACATGGAC TGCTTCATCT 780
GCTGTATCCT CTCCCATGGA GACAAGGGCA TCATCTATGG CACTGATGGA CAGGAGGCC 840
CCATCTATGA GCTGACATCT CAGTTCAC TGTTGAAGTG CCCTTCCCTT GCTGGAAAAC 900
CCAAAGTGTT TTTTATTGAG GCTTGTCAGG GGGATAACTA CCAGAAAGGT ATACCTGTTG 960
AGACTGATTC AGAGGAGCAA CCCTATTTAG AAATGGATTT ATCATCACCT CAAACGAGAT 1020
ATATCCCGGA TGAGGCTGAC TTTCTGCTGG GGATGGCCAC TGTGAATAAC TGTGTTTCCT 1080
ACCGAAACCC TGCAGAGGGA ACCTGGTACA TCCAGTCACT TTGCCAGAGC CTGAGAGAGC 1140
GATGTCCTCG AGGCGATGAT ATTCTCACC TCCTGACTGA AGTGAAC TAT GAAGTAAGCA 1200
ACAAGGATGA CAAGAAAAC ATGGGGAAAC AGATGCCTCA GCCTACTTTC AACTAAGAA 1260
AAAACTTGT CTTCCCTTCT GATTGA 1286

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 81 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Asp Phe Ser Arg Asn Leu Tyr Asp Ile Gly Glu Gln Leu Asp Ser
 1           5           10           15
Glu Asp Leu Ala Ser Leu Lys Phe Leu Ser Leu Asp Tyr Ile Pro Gln
          20           25           30
Arg Lys Gln Glu Pro Ile Lys Asp Ala Leu Met Leu Phe Gln Arg Leu
        35           40           45
Gln Glu Lys Arg Met Leu Glu Glu Ser Asn Leu Ser Phe Leu Lys Glu
       50           55           60
Leu Leu Phe Arg Ile Asn Arg Leu Asp Leu Leu Ile Thr Tyr Leu Asn
      65           70           75           80
Thr

```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATGGACTTCA GCAGAAATCT TTATG

25

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TCAATCAGAA GGAAGACAA GTTTT

25

-68-

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TTTGTCCAAA GTCTTTGCTG AATT

24

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TGGAGATTTC CTCTTGCAAA AGAAACTTA

29

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GATAGAGCAT TTGGAGATTT CC

22

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CTTTTCAGGG TAAACTCAAT TCTG

24

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1440 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATGGACTTCA GCAGAAATCT TTATGATATT GGGGAACAAC TGGACAGTGA AGATCTGGCC	60
TCCCTCAAGT TCCTGAGCCT GGAATACATT CCGCAAAGGA AGCAAGAACC CATCAAGGAT	120
GCCTTGATGT TATTCCAGAG ACTCCAGGAA AAGAGAATGT TGGAGGAAAG CAATCTGTCC	180
TTCTGAAGG AGCTGCTCTT CCGAATTAAT AGACTGGATT TGCTGATTAC CTACCTAAAC	240

-69-

ACTAGAAAGG	AGGAGATGGA	AAGGGAACCT	CAGACACCAG	GCAGGGCTCA	AATTTCTGCC	300
TACAGGGTCA	TGCTCTATCA	GATTTTCAGAA	GAAGTGAGCA	GATCAGAATT	GAGGTCTTTT	360
AAGTTTCTTT	TGCAAGAGGA	AATCTCCAAA	TGCAAACTGG	ATGATGACAT	GAACCTGCTG	420
GATATTTTCA	TAGAGATGGA	GAAGAGGGTC	ATCCTGGGAG	AAGGAAAGTT	GGACATCCTG	480
AAAAGAGTCT	GTGCCCCAAT	CAACAAGAGC	CTGCTGAAGA	TAATCAACGA	CTATGAAGAA	540
TTTCAGCAAAG	AGAGAAGCAG	CAGCCTTGAA	GGAAGTCCTG	ATGAATTTTC	AAATGGGGAG	600
GAGTTGTGTG	GGGTAATGAC	AATCTCGGAC	TCTCCAAGAG	AACAGGATAG	TGAATCACAG	660
ACTTTGGACA	AAGTTTACCA	AATGAAAAGC	AAACCTCGGG	GATACTGTCT	GATCATCAAC	720
AATCACAATT	TTGCAAAAAGC	ACGGGAGAAA	GTGCCCCAAC	TTCACAGCAT	TAGGGACAGG	780
AATGGAACAC	ACTTGGATGC	AGGGGCTTTG	ACCACGACCT	TTGAAGAGCT	TCATTTTGAG	840
ATCAAGCCCC	ACGATGACTG	CACAGTAGAG	CAAATCTATG	AGATTTTGAA	AATCTACCAA	900
CTCATGGACC	ACAGTAACAT	GGACTGCTTC	ATCTGCTGTA	TCCTCTCCCA	TGGAGACAAG	960
GGCATCATCT	ATGGCACTGA	TGGACAGGAG	CCCCCATCT	ATGAGCTGAC	ATCTCAGTTC	1020
ACTGGTTTGA	ACTGCCCTTC	CCTTGCTGGA	AAACCCAAAG	TGTTTTTTAT	TCAGGCTTGT	1080
CAGGGGGATA	ACTACCAGAA	AGGTATACCT	ATTGAGACTG	ATTCAGAGGA	GCAACCCATAT	1140
TTAGAAATGG	ATTTATCATC	ACCTCAAACG	AGATATATCC	CGGATGAGGC	TGACTTTCTG	1200
CTGGGGATGG	CCACTGTGAA	TAAGTGTGTT	TCCTACCGAA	ACCCTGCAGA	GGGAACCTGG	1260
TACATCCAGT	CACCTTGCCA	GAGCCTGAGA	GAGCGATGTC	CTCGAGGCCA	TGATATTCTC	1320
ACCATCCTGA	CTGAAGTGAA	CTATGAAGTA	AGCAACAAGG	ATGACAAGAA	AAACATGGGG	1380
AAACAGATGC	CTCAGCCTAC	TTTCACACTA	AGAAAAAACC	TTGTCTTCCC	TTCTGATTGA	1440

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 479 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met	Asp	Phe	Ser	Arg	Asn	Leu	Tyr	Asp	Ile	Gly	Glu	Gln	Leu	Asp	Ser
1				5				10					15		
Glu	Asp	Leu	Ala	Ser	Leu	Lys	Phe	Leu	Ser	Leu	Asp	Tyr	Ile	Pro	Gln
		20						25					30		
Arg	Lys	Gln	Glu	Pro	Ile	Lys	Asp	Ala	Leu	Met	Leu	Phe	Gln	Arg	Leu
		35					40					45			
Gln	Glu	Lys	Arg	Met	Leu	Glu	Glu	Ser	Asn	Leu	Ser	Phe	Leu	Lys	Glu
	50					55				60					
Leu	Leu	Phe	Arg	Ile	Asn	Arg	Leu	Asp	Leu	Leu	Ile	Thr	Tyr	Leu	Asn
	65				70					75				80	
Thr	Arg	Lys	Glu	Glu	Met	Glu	Arg	Glu	Leu	Gln	Thr	Pro	Gly	Arg	Ala
			85					90						95	
Gln	Ile	Ser	Ala	Tyr	Arg	Val	Met	Leu	Tyr	Gln	Ile	Ser	Glu	Glu	Val
		100					105						110		
Ser	Arg	Ser	Glu	Leu	Arg	Ser	Phe	Lys	Phe	Leu	Leu	Gln	Glu	Glu	Ile
		115					120					125			
Ser	Lys	Cys	Lys	Leu	Asp	Asp	Asp	Met	Asn	Leu	Leu	Asp	Ile	Phe	Ile
	130				135					140					
Glu	Met	Glu	Lys	Arg	Val	Ile	Leu	Gly	Glu	Gly	Lys	Leu	Asp	Ile	Leu
	145				150				155					160	
Lys	Arg	Val	Cys	Ala	Gln	Ile	Asn	Lys	Ser	Leu	Leu	Lys	Ile	Ile	Asn
			165					170						175	
Asp	Tyr	Glu	Glu	Phe	Ser	Lys	Glu	Arg	Ser	Ser	Ser	Leu	Glu	Gly	Ser
		180					185						190		
Pro	Asp	Glu	Phe	Ser	Asn	Gly	Glu	Glu	Leu	Cys	Gly	Val	Met	Thr	Ile
		195					200					205			
Ser	Asp	Ser	Pro	Arg	Glu	Gln	Asp	Ser	Glu	Ser	Gln	Thr	Leu	Asp	Lys
	210					215					220				
Val	Tyr	Gln	Met	Lys	Ser	Lys	Pro	Arg	Gly	Tyr	Cys	Leu	Ile	Ile	Asn
	225				230					235				240	
Asn	His	Asn	Phe	Ala	Lys	Ala	Arg	Glu	Lys	Val	Pro	Lys	Leu	His	Ser
			245					250						255	
Ile	Arg	Asp	Arg	Asn	Gly	Thr	His	Leu	Asp	Ala	Gly	Ala	Leu	Thr	Thr

-70-

			260					265					270				
Thr	Phe	Glu	Glu	Leu	His	Phe	Glu	Ile	Lys	Pro	His	Asp	Asp	Cys	Thr		
		275					280					285					
Val	Glu	Gln	Ile	Tyr	Glu	Ile	Leu	Lys	Ile	Tyr	Gln	Leu	Met	Asp	His		
	290					295					300						
Ser	Asn	Met	Asp	Cys	Phe	Ile	Cys	Cys	Ile	Leu	Ser	His	Gly	Asp	Lys		
305					310					315					320		
Gly	Ile	Ile	Tyr	Gly	Thr	Asp	Gly	Gln	Glu	Pro	Pro	Ile	Tyr	Glu	Leu		
				325					330					335			
Thr	Ser	Gln	Phe	Thr	Gly	Leu	Lys	Cys	Pro	Ser	Leu	Ala	Gly	Lys	Pro		
			340					345					350				
Lys	Val	Phe	Phe	Ile	Gln	Ala	Cys	Gln	Gly	Asp	Asn	Tyr	Gln	Lys	Gly		
		355					360					365					
Ile	Pro	Val	Glu	Thr	Asp	Ser	Glu	Glu	Gln	Pro	Tyr	Leu	Glu	Met	Asp		
	370					375					380						
Leu	Ser	Ser	Pro	Gln	Thr	Arg	Tyr	Ile	Pro	Asp	Glu	Ala	Asp	Phe	Leu		
385					390					395					400		
Leu	Gly	Met	Ala	Thr	Val	Asn	Asn	Cys	Val	Ser	Tyr	Arg	Asn	Pro	Ala		
				405				410						415			
Glu	Gly	Thr	Trp	Tyr	Ile	Gln	Ser	Leu	Cys	Gln	Ser	Leu	Arg	Glu	Arg		
			420					425					430				
Cys	Pro	Arg	Gly	Asp	Asp	Ile	Leu	Thr	Ile	Leu	Thr	Glu	Val	Asn	Tyr		
		435					440					445					
Glu	Val	Ser	Asn	Lys	Asp	Asp	Lys	Lys	Asn	Met	Gly	Lys	Gln	Met	Pro		
	450					455					460						
Gln	Pro	Thr	Phe	Thr	Leu	Arg	Lys	Lys	Leu	Val	Phe	Pro	Ser	Asp			
465					470					475							

- 71 -

What is claimed is:

1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide that is at least 85% identical to SEQ ID NO:2.
- 5 2. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide that is at least 85% identical to SEQ ID NO:4.
3. The nucleic acid molecule of claim 1 or claim 2, said molecule encoding a polypeptide capable of
10 selectively binding to the death effector domain of FADD.
4. The nucleic acid molecule of claim 1, said molecule encoding the amino acid sequence of SEQ ID NO:2.
5. The nucleic acid molecule of claim 4, said molecule comprising the nucleotide sequence of SEQ ID
15 NO:3.
6. The nucleic acid molecule of claim 2, said molecule encoding the amino acid sequence of SEQ ID NO:4.
7. The nucleic acid molecule of claim 6, said molecule comprising the nucleotide sequence of SEQ ID
20 NO:2.
8. An isolated nucleic acid molecule, said molecule comprising the cDNA sequence contained within ATCC Accession No. 97877.
9. An isolated nucleic acid molecule, said
25 molecule comprising the cDNA sequence contained within ATCC Accession No. 97878.

- 72 -

10. A vector comprising the nucleic acid molecule of claim 1, claim 2, claim 4, or claim 6.

11. The vector of claim 10, said vector being an expression vector.

5 12. The vector of claim 11, further comprising a regulatory element.

13. The vector of claim 12, wherein the regulatory element is selected from the group consisting of the cytomegalovirus HCMV immediate early gene, the
10 early promoter of SV40 adenovirus, the late promoter of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage λ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the
15 promoters of acid phosphatase, and the promoters of the yeast α -mating factors.

14. The vector of claim 12, wherein said regulatory element directs tissue-specific expression.

15. The vector of claim 10, further comprising a
20 reporter gene.

16. The vector of claim 15, wherein the reporter gene is selected from the group consisting of β -lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside
25 phosphotransferase (neo^r , $G418^r$), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding β -galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT).

- 73 -

17. The vector of claim 10, wherein said vector is a plasmid.

18. The vector of claim 10, wherein said vector is a virus.

5 19. The vector of claim 18, wherein said virus is a retrovirus.

20. A genetically engineered host cell comprising the expression vector of claim 11.

21. The cell of claim 20, wherein said cell is
10 eukaryotic.

22. A substantially pure polypeptide having the amino acid sequence encoded by the nucleic acid molecule of claim 1, claim 2, claim 4, or claim 6.

23. The polypeptide of claim 22, further
15 comprising a heterologous polypeptide other than a Caspase-8 polypeptide.

24. An antibody that binds Caspase-8h.

25. An antibody that binds Caspase-8i.

26. A transgenic animal harboring the nucleic
20 acid molecule of claim 1, claim 2, claim 4, or claim 6.

27. A method of determining whether a patient is suffering from a disorder associated with an abnormal rate of apoptotic cell death, said method comprising obtaining a biological sample from said patient and

- 74 -

quantitating the level of caspase-8h expression in said biological sample.

28. The method of claim 27, comprising quantitating mRNA encoding Caspase-8h.

5 29. The method of claim 27, comprising quantitating Caspase-8h protein.

30. A method of determining whether a patient is suffering from a disorder associated with an abnormal rate of apoptotic cell death, said method comprising
10 obtaining a biological sample from said patient and quantitating the level of caspase-8i expression in said biological sample.

31. The method of claim 30, comprising quantitating mRNA encoding Caspase-8i.

15 32. The method of claim 30, comprising quantitating Caspase-8i protein.

33. The method of claim 28 or claim 31, comprising an RNase protection assay, Northern blot analysis, or amplification by RT-PCR.

20 34. The method of claim 29 or claim 32, comprising Western blot analysis.

35. The method of claim 27 or claim 30, wherein said biological sample is a tumor sample.

36. A method of treating a patient who is
25 suffering from a disorder associated with abnormal activity of the Fas/APO-1 receptor complex, said method

- 75 -

comprising administering to the patient a compound that modulates the expression or activity of Caspase-8h.

37. The method of claim 36, wherein the compound comprises a small molecule, an antisense nucleic acid
5 molecule, or a ribozyme.

38. A method of treating a patient who is suffering from a disorder associated with an abnormal activity of the TNF receptor complex, said method comprising administering to the patient a compound that
10 modulates the expression or activity of Caspase-8i.

39. The method of claim 38, wherein the compound comprises a small molecule, an antisense nucleic acid molecule, or a ribozyme.

40. A therapeutic composition comprising the
15 compound of claim 36 or claim 38.

41. A method for treating a patient who is suffering from a disorder associated with abnormal activity of the Fas/APO-1 receptor complex, said method comprising administering a compound that mediates
20 oligomerization between the Fas/APO-1 receptor complex and Caspase-8h or Caspase-8i.

42. A method for treating a patient who is suffering from a disorder associated with abnormal activity of the TNF receptor complex, said method
25 comprising administering a compound that mediates oligomerization between the TNF receptor complex and Caspase-8h or Caspase-8i.

- 76 -

43. The method of claim 41 or claim 42, wherein the patient is suffering from acquired immune deficiency syndrome (AIDS), a neurodegenerative disorder, a myelodysplastic syndrome, an ischemic injury, or a
5 toxin-induced injury.

44. The method of claim 41 or claim 42, wherein the compound is synthetic.

45. A method of treating a patient who is suffering from a disorder associated with excessive
10 apoptotic cell death, said method comprising administering to the patient the nucleic acid molecule of claim 1 or claim 2.

46. A method of treating a patient who is suffering from a disorder associated with excessive
15 apoptotic cell death, said method comprising administering to the patient the polypeptide of claim 22.

47. A method of identifying a compound that modulates expression of Caspase-8h, said method comprising assessing the expression of Caspase-8h in the
20 presence and absence of said compound.

48. A method of identifying a compound that modulates expression of Caspase-8i, said method comprising assessing the expression of Caspase-8i in the presence and absence of said compound.

25 49. A method for treating a patient who is suffering from a disease characterized by an abnormally low rate of apoptotic cell death, said method comprising administering a compound that mediates oligomerization

- 77 -

between the Fas/APO-1 receptor complex and Caspase-8h or Caspase-8i.

50. A method for treating a patient who is suffering from a disease characterized by an abnormally low rate of apoptotic cell death, said method comprising administering a compound that mediates oligomerization between the TNF receptor complex and Caspase-8h or Caspase-8i.

51. A method of identifying a compound that modulates the activity of Caspase-8h, said method comprising assessing the activity of Caspase-8h in the presence and absence of said compound.

52. A method of identifying a compound that modulates the activity of Caspase-8i, said method comprising assessing the activity of Caspase-8i in the presence and absence of said compound.

53. A method for determining whether a selected compound modulates oligomerization between the Fas/APO-1 receptor complex and Caspase-8h or Caspase-8i, said method comprising measuring oligomerization of the Fas/APO-1 receptor complex and Caspase-8h or Caspase-8i in the presence and absence of said selected compound.

54. A method for determining whether a selected compound modulates oligomerization between the TNF receptor complex and Caspase-8h or Caspase-8i, said method comprising measuring oligomerization of the TNF receptor complex and Caspase-8h or Caspase-8i in the presence and absence of said selected compound.

- 78 -

55. An isolated nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, said isolated nucleic acid molecule encoding Caspase-8h.

5 56. An isolated nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:3, said isolated nucleic acid molecule encoding Caspase-8i.

57. An isolated nucleic acid molecule comprising
10 a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO:1, said isolated nucleic acid molecule encoding Caspase-8h.

58. An isolated nucleic acid molecule comprising
a nucleotide sequence which is at least 90% identical to
15 the nucleotide sequence of SEQ ID NO:3, said isolated nucleic acid molecule encoding Caspase-8i.

1/5




FIG. 1

2/5

ATG	GAC	TTC	AGC	AGA	AAT	CTT	TAT	GAT	ATT	GGG	GAA	CAA	CTG	42
GAC	AGT	GAA	GAT	CTG	GCC	TCC	CTC	AAG	TTC	CTG	AGC	CTG	GAC	84
TAC	ATT	CCG	CAA	AGG	AAG	CAA	GAA	CCC	ATC	AAG	GAT	GCC	TTG	126
ATG	TTA	TTC	CAG	AGA	CTC	CAG	GAA	AAG	AGA	ATG	TTG	GAG	GAA	168
AGC	AAT	CTG	TCC	TTC	CTG	AAG	GAG	CTG	CTC	TTC	CGA	ATT	AAT	210
AGA	CTG	GAT	TTG	CTG	ATT	ACC	TAC	CTA	AAC	ACT	AGA	AAG	GAG	252
GAG	ATG	GAA	AGG	GAA	CTT	CAG	ACA	CCA	GGC	AGG	GCT	CAA	ATT	294
TCT	GCC	TAC	AGG	GTC	ATG	CTC	TAT	CAG	ATT	TCA	GAA	GAA	GTG	336
AGC	AGA	TCA	GAA	TTG	AGG	TCT	TTT	AAG	TTT	CTT	TTG	CAA	GAG	378
GAA	ATC	TCC	AAA	TGC	AAA	CTG	GAT	GAT	GAC	ATG	AAC	CTG	CTG	420
GAT	ATT	TTT	ATA	GAG	ATG	GAG	AAG	AGG	GTC	ATC	CTG	GGA	GAA	462
GGA	AAG	TTG	GAC	ATC	CTG	AAA	AGA	GTC	TGT	GCC	CAA	ATC	AAC	504
AAG	AGC	CTG	CTG	AAG	ATA	ATC	AAC	GAC	TAT	GAA	GAA	TTC	AGC	546
AAA	GAC	TTT	GGA	CAA	AGT	TTA	CCA	AAT	GAA	AAG	CAA	ACC	TCG	588
GGG	ATA	CTG	TCT	GAT	CAT	CAA	CAA	TCA	CAA	TTT	TGC	AAA	AGC	630
ACG	GGA	GAA	AGT	GCC	CAA	ACT	TCA	CAG	CAT	TAG	GGA	CAG	GAA	672
TGG	AAC	ACA	CTT	GGA	TGC	AGG	GGC	TTT	GAC	CAC	GAC	CTT	TGA	714
AGA	GCT	TCA	TTT	TGA	GAT	CAA	GCC	CCA	CGA	TGA	CTG	CAC	AGT	756
AGA	GCA	AAT	CTA	TGA	GAT	TTT	GAA	AAT	CTA	CCA	ACT	CAT	GGA	798
CCA	CAG	TAA	CAT	GGA	CTG	CTT	CAT	CTG	CTG	TAT	CCT	CTC	CCA	840
TGG	AGA	CAA	GGG	CAT	CAT	CTA	TGG	CAC	TGA	TGG	ACA	GGA	GGC	882
CCC	CAT	CTA	TGA	GCT	GAC	ATC	TCA	GTT	CAC	TGG	TTT	GAA	GTG	924
CCC	TTC	CCT	TGC	TGG	AAA	ACC	CAA	AGT	GTT	TTT	TAT	TCA	GGC	966
TTG	TCA	GGG	GGA	TAA	CTA	CCA	GAA	AGG	TAT	ACC	TGT	TGA	GAC	1008
TGA	TTT	AGA	GGA	GCA	ACC	CTA	TTT	AGA	AAT	GGA	TTT	ATC	ATC	1050
ACC	TCA	AAC	GAG	ATA	TAT	CCC	GGA	TGA	GGC	TGA	CTT	TCT	GCT	1092
GGG	GAT	GGC	CAC	TGT	GAA	TAA	CTG	TGT	TTC	CTA	CCG	AAA	CCC	1134
TGC	AGA	GGG	AAC	CTG	GTA	CAT	CCA	GTC	ACT	TTG	CCA	GAG	CCT	1176
GAG	AGA	GCG	ATG	TCC	TCG	AGG	CGA	TGA	TAT	TCT	CAC	CAT	CCT	1218
GAC	TGA	AGT	GAA	CTA	TGA	AGT	AAG	CAA	CAA	GGA	TGA	CAA	GAA	1260
AAA	CAT	GGG	GAA	ACA	GAT	GCC	TCA	GCC	TAC	TTT	CAC	ACT	AAG	1302
AAA	AAA	ACT	TGT	CTT	CCC	TTC	TGA	TTG	A	1330	(SEQ. ID. NO: 1)			

FIG. 2

MDFSRLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPKID 40
 ALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLN 80
 TRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSLSRF 120
 KFLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDIL 160
 KRVCAQINKSLLKIINDYEEFSKDFGQSLPNEKQTSGLS 200
 DHQQSQFCKSTGESAQTSQH. 221 (SEQ. ID. NO.: 2)

FIG. 3

SUBSTITUTE SHEET (RULE 26)

3/5

ATG	GAC	TTC	AGC	AGA	AAT	CTT	TAT	GAT	ATT	GGG	GAA	CAA	CTG	42
GAC	AGT	GAA	GAT	CTG	GCC	TCC	CTC	AAG	TTC	CTG	AGC	CTG	GAC	84
TAC	ATT	CCG	CAA	AGG	AAG	CAA	GAA	CCC	ATC	AAG	GAT	GCC	TTG	126
ATG	TTA	TTC	CAG	AGA	CTC	CAG	GAA	AAG	AGA	ATG	TTG	GAG	GAA	168
AGC	AAT	CTG	TCC	TTC	CTG	AAG	GAG	CTG	CTC	TTC	CGA	ATT	AAT	210
AGA	CTG	GAT	TTG	CTG	ATT	ACC	TAC	CTA	AAC	ACT	TAA	GTT	TCT	252
TTT	GCA	AGA	GGA	AAT	CTC	CAA	ATG	CTC	TAT	CAG	ATT	TCA	GAA	294
GAA	GTG	AGC	AGA	TCA	GAA	TTG	AGT	TTA	CCC	TGA	AAA	GAG	TCT	336
GTG	CCC	AAA	TCA	ACA	AGA	GCC	TGC	TGA	AGA	TAA	TCA	ACG	ACT	378
ATG	AAG	AAT	TCA	GCA	AAG	AGA	GAA	GCA	GCA	GCC	TTG	AAG	GAA	420
GTC	CTG	ATG	AAT	TTT	CAA	ATG	GGG	AGG	AGT	TGT	GTG	GGG	TAA	462
TGA	CAA	TCT	CGG	ACT	CTC	CAA	GAG	AAC	AGG	ATA	GTG	AAT	CAC	504
AGA	CTT	TGG	ACA	AAG	TTT	ACC	AAA	TGA	AAA	GCA	AAC	CTC	GGG	546
GAT	ACT	GTC	TGA	TCA	TCA	ACA	ATC	ACA	ATT	TTG	CAA	AAG	CAC	588
GGG	AGA	AAG	TGC	CCA	AAC	TTC	ACA	GCA	TTA	GGG	ACA	GGA	ATG	630
GAA	CAC	ACT	TGG	ATG	CAG	GGG	CTT	TGA	CCA	CGA	CCT	TTG	AAG	672
AGC	TTC	ATT	TTG	AGA	TCA	AGC	CCC	ACG	ATG	ACT	GCA	CAG	TAG	714
AGC	AAA	TCT	ATG	AGA	TTT	TGA	AAA	TCT	ACC	AAC	TCA	TGG	ACC	756
ACA	GTA	ACA	TGG	ACT	GCT	TCA	TCT	GCT	GTA	TCC	TCT	CCC	ATG	798
GAG	ACA	AGG	GCA	TCA	TCT	ATG	GCA	CTG	ATG	GAC	AGG	AGG	CCC	840
CCA	TCT	ATG	AGC	TGA	CAT	CTC	AGT	TCA	CTG	GTT	TGA	AGT	GCC	882
CTT	CCC	TTG	CTG	GAA	AAC	CCA	AAG	TGT	TTT	TTA	TTC	AGG	CTT	924
GTC	AGG	GGG	ATA	ACT	ACC	AGA	AAG	GTA	TAC	CTG	TTG	AGA	CTG	966
ATT	CAG	AGG	AGC	AAC	CCT	ATT	TAG	AAA	TGG	ATT	TAT	CAT	CAC	1008
CTC	AAA	CGA	GAT	ATA	TCC	CGG	ATG	AGG	CTG	ACT	TTC	TGC	TGG	1050
GGA	TGG	CCA	CTG	TGA	ATA	ACT	GTG	TTT	CCT	ACC	GAA	ACC	CTG	1092
CAG	AGG	GAA	CCT	GGT	ACA	TCC	AGT	CAC	TTT	GCC	AGA	GCC	TGA	1134
GAG	AGC	GAT	GTC	CTC	GAG	GCG	ATG	ATA	TTC	TCA	CCA	TCC	TGA	1176
CTG	AAG	TGA	ACT	ATG	AAG	TAA	GCA	ACA	AGG	ATG	ACA	AGA	AAA	1218
ACA	TGG	GGA	AAC	AGA	TGC	CTC	AGC	CTA	CTT	TCA	CAC	TAA	GAA	1260
AAA	AAC	TTG	TCT	TCC	CTT	CTG	ATT	GA	1286	(SEQ. ID. NO.: 3)				

FIG. 4

MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPKID 40
 ALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLN 80
 T. 82 (SEQ. ID. NO.: 4)

FIG. 5

4/5

ATG	GAC	TTC	AGC	AGA	AAT	CTT	TAT	GAT	ATT	GGG	GAA	CAA	CTG	42
GAC	AGT	GAA	GAT	CTG	GCC	TCC	CTC	AAG	TTC	CTG	AGC	CTG	GAC	84
TAC	ATT	CCG	CAA	AGG	AAG	CAA	GAA	CCC	ATC	AAG	GAT	GCC	TTG	126
ATG	TTA	TTC	CAG	AGA	CTC	CAG	GAA	AAG	AGA	ATG	TTG	GAG	GAA	168
AGC	AAT	CTG	TCC	TTC	CTG	AAG	GAG	CTG	CTC	TTC	CGA	ATT	AAT	210
AGA	CTG	GAT	TTG	CTG	ATT	ACC	TAC	CTA	AAC	ACT	AGA	AAG	GAG	252
GAG	ATG	GAA	AGG	GAA	CTT	CAG	ACA	CCA	GGC	AGG	GCT	CAA	ATT	294
TCT	GCC	TAC	AGG	GTC	ATG	CTC	TAT	CAG	ATT	TCA	GAA	GAA	GTG	336
AGC	AGA	TCA	GAA	TTG	AGG	TCT	TTT	AAG	TTT	CTT	TTG	CAA	GAG	378
GAA	ATC	TCC	AAA	TGC	AAA	CTG	GAT	GAT	GAC	ATG	AAC	CTG	CTG	420
GAT	ATT	TTC	ATA	GAG	ATG	GAG	AAG	AGG	GTC	ATC	CTG	GGA	GAA	462
GGA	AAG	TTG	GAC	ATC	CTG	AAG	AGA	GTC	TGT	GCC	CAA	ATC	AAC	504
AAG	AGC	CTG	CTG	AAG	ATA	ATC	AAC	GAC	TAT	GAA	GAA	TTC	AGC	546
AAA	GAG	AGA	AGC	AGC	AGC	CTT	GAA	GGA	AGT	CCT	GAT	GAA	TTT	588
TCA	AAT	GGG	GAG	GAG	TTG	TGT	GGG	GTA	ATG	ACA	ATC	TCG	GAC	630
TCT	CCA	AGA	GAA	CAG	GAT	AGT	GAA	TCA	CAG	ACT	TTG	GAC	AAA	672
GTT	TAC	CAA	ATG	AAA	AGC	AAA	CCT	CGG	GGA	TAC	TGT	CTG	ATC	714
ATC	AAC	AAT	CAC	AAT	TTT	GCA	AAA	GCA	CGG	GAG	AAA	GTG	CCC	756
AAA	CTT	CAC	AGC	ATT	AGG	GAC	AGG	AAT	GGA	ACA	CAC	TTG	GAT	798
GCA	GGG	GCT	TTG	ACC	ACG	ACC	TTT	GAA	GAG	CTT	CAT	TTT	GAG	840
ATC	AAG	CCC	CAC	GAT	GAC	TGC	ACA	GTA	GAG	CAA	ATC	TAT	GAG	882
ATT	TTG	AAA	ATC	TAC	CAA	CTC	ATG	GAC	CAC	AGT	AAC	ATG	GAC	924
TGC	TTC	ATC	TGC	TGT	ATC	CTC	TCC	CAT	GGA	GAC	AAG	GGC	ATC	966
ATC	TAT	GGC	ACT	GAT	GGA	CAG	GAG	CCC	CCC	ATC	TAT	GAG	CTG	1008
ACA	TCT	CAG	TTC	ACT	GGT	TTG	AAG	TGC	CCT	TCC	CTT	GCT	GGA	1050
AAA	CCC	AAA	GTG	TTT	TTT	ATT	CAG	GCT	TGT	CAG	GGG	GAT	AAC	1092
TAC	CAG	AAA	GGT	ATA	CCT	GTT	GAG	ACT	GAT	TCA	GAG	GAG	CAA	1134
CCC	TAT	TTA	GAA	ATG	GAT	TTA	TCA	TCA	CCT	CAA	ACG	AGA	TAT	1176
ATC	CCG	GAT	GAG	GCT	GAC	TTT	CTG	CTG	GGG	ATG	GCC	ACT	GTG	1218
AAT	AAC	TGT	GTT	TCC	TAC	CGA	AAC	CCT	GCA	GAG	GGA	ACC	TGG	1260
TAC	ATC	CAG	TCA	CTT	TGC	CAG	AGC	CTG	AGA	GAG	CGA	TGT	CCT	1302
CGA	GGC	GAT	GAT	ATT	CTC	ACC	ATC	CTG	ACT	GAA	GTG	AAC	TAT	1344
GAA	GTA	AGC	AAC	AAG	GAT	GAC	AAG	AAA	AAC	ATG	GGG	AAA	CAG	1386
ATG	CCT	CAG	CCT	ACT	TTC	ACA	CTA	AGA	AAA	AAA	CTT	GTC	TTC	1428
CCT	TCT	GAT	TGA											1440 (SEQ. ID. NO.: 11)

FIG. 6


MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPKID	40
ALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLN	80
TRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSSELRSF	120
KFLLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDIL	160
KRVCAQINKSLLKIINDYEEFSKERSSSLEGGSPDEFSGE	200
ELCGVMTISDSPREQDSESQTLDKVYQMKSKPRGYCLIIIN	240
NHNFAKAREKVPKLHSIRDNRNGTHLDAGALTTTFFELHFE	280
IKPHDDCTVEQIYEILKIYQLMDHSNMDCFICILSHGDK	320
GIIYGTGQEPPIYELTSQFTGLKCPSLAGKPKVFFFIQAC	360
QGDNYQKGIPVETDSEEQPYLEMDLSSPQTRYIPDEADFL	400
LGMATVNNCVSYRNPAGETWYIQSLCQSLRERCPRGDDIL	440
TILTEVNYESVSNKDDKKNMGKQMPQPTFTLRKKLVFSPD.	480

(SEQ. ID. NO.: 12)

FIG. 7

SUBSTITUTE SHEET (RULE 26)

5/5

**FIG. 8**

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/03702

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 19/00, 21/04; C12N 15/64

US CL : 536/23.1, 23.5; 435/91.4, 91.41, 172.3

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5; 435/91.4, 91.41, 172.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, USPATFUL, WPIDS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	BOLDIN et al. Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death. Cell. 14 June 1996, Vol. 85, pages 803-815, especially pages 805 and 806.	1-7, 10-12, 55-58 ----- 8, 9, 13-21
Y	SAMBROOK et al. 'Expression of Cloned Genes in Cultured Mammalian Cells'. In: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press. 1989, pages 16.1-16.31.	8, 9, 13-21
Y	SAMBROOK et al. 'Expression of Cloned Genes in Escherichia coli'. In: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press. 1989, pages 17.1-17.10.	8, 9, 13-21



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*g* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 JUNE 1998

Date of mailing of the international search report

08 JUL 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JEFFREY S. PARKIN, PH.D.

Telephone No. (703) 308-0196



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/03702

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-21 and 55-58

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/03702

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claim(s) 1-21 and 55-58, drawn to isolated nucleic acids encoding Caspase-8h and -8i and nucleic acid probes.

Group II, claim(s) 22 and 23, drawn to polypeptides.

Group III, claim(s) 24 and 25, drawn to Caspase-specific antibodies.

Group IV, claim(s) 26, drawn to a transgenic animal containing nucleic acids encoding Caspase-8h and -8i.

Group V, claim(s) 27-35, drawn to methods for determining if a patient is suffering from disorders associated with abnormal apoptotic rates.

Group VI, claim(s) 36, 37, 41, 43, and 44, drawn to methods of treating patients suffering from disorders associated with abnormal Fas/APO-1 receptor complex activity.

Group VII, claim(s) 38, 39, and 42-44, drawn to methods of treating patients suffering from disorders associated with abnormal TNF receptor complex activity.

Group VIII, claim(s) 40, drawn to a therapeutic composition for treating patients suffering from disorders associated with abnormal Fas/APO-1 receptor complex activity.

Group IX, claim(s) 40, drawn to a therapeutic composition for treating patients suffering from disorders associated with abnormal TNF receptor complex activity.

Group X, claim(s) 45, drawn to nucleic acid-based treatments for patients suffering from disorders associated with excessive apoptoses.

Group XI, claim(s) 46, drawn to peptide-based treatments for patients suffering from disorders associated with excessive apoptoses.

Group XII, claim(s) 47 and 48, drawn to methods of identifying compounds that modulate Caspase-8 expression.

Group XIII, claim(s) 49 and 50, drawn to methods of treating patients suffering from a disease caused by abnormally low apoptotic rates.

Group XIV, claim(s) 51 and 52, drawn to methods of identifying compounds capable of modulating Caspase-8 activity.

Group XV, claim(s) 53, drawn to methods of identifying compounds capable of modulating oligomerization of the Fas/APO-1 receptor complex and Caspase-8.

Group XVI, claim 54, drawn to methods of identifying compounds capable of modulating oligomerization of the TNF receptor complex and Caspase-8.

The inventions listed as Groups I-XVI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions of Groups I-IV, VIII, and IX are all directed toward different products (e.g., nucleic acids; polypeptides; antibodies; and, transgenic animals) with disparate chemical structures, functions, and methods of making. Accordingly, each group does not share a special technical feature.

The inventions of Groups V-VII and X-XVI are all directed toward different methodologies (e.g., methods of treating Fas/APO-1 receptor complex abnormalities; methods of treating TNF receptor complex abnormalities; methods of identifying modulators of Caspase expression; and, methods of identifying modulators of Caspase activity). As such, each methodology will employ different scientific reagents, methodology steps, and accomplishes a different scientific objective. Accordingly, each group does not share a special technical feature.

The inventions of Groups I-IV/VIII/IX and V-VIII/X-XVI are all directed toward different products (I-IV/VIII/IX) and methods (V-VIII/X-XVI). The products are not required to practice all of the method steps claimed and the claimed methodologies do not require all the products claimed. Accordingly, each of the aforementioned groups lack a special technical feature and are clearly drawn toward different inventive entities.